Biotech Industry Financials, Performance and Ratios
-
Industry Score
34.7 /100
Rank 80 out of 131 Industries -
Advance/Decline
47/259
-
No. of Companies306
-
Avg. Market Cap3,650
-
Price to Earning Ratio6.52
-
Price to Earning Growth Ratio1.01
-
Price to Book Ratio15.64
-
Return on Equity14.04
-
Return on Capital Employed-
-
Return on Assets8.49
-
Dividend yield 1 year %0.21 %
-
Net Profit Growth Annual YoY %61.57 %
-
Net Profit Growth Qtr YoY %-171.49 %
-
Net Profit Growth Qtr QoQ %-264.89 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
11,276.5
|
22.6
|
L
 -1.6%
H
22.5
23.4
|
L
 -1.9%
H
22.2
23.6
|
L
 -5.8%
H
22.2
25.4
|
L
 -5.6%
H
21.3
28.0
|
L
 18.6%
H
18.5
28.0
|
L
 100.6%
H
8.0
28.0
|
L
 -29.0%
H
7.9
35
|
L
H
7.9
37.6
|
| IQVIA |
|
44,089.8
|
267.9
|
L
 -0.8%
H
267.4
277.4
|
L
 -0.7%
H
264.9
277.4
|
L
 3.1%
H
252.5
277.4
|
L
 59.6%
H
168.8
277.4
|
L
 42.6%
H
154.5
277.4
|
L
 34.8%
H
134.6
277.4
|
L
 3.1%
H
134.6
285.6
|
L
 242.8%
H
70.1
285.6
|
| Nuvation Bio Inc (Class A) |
|
2,004.9
|
5.7
|
L
 -6.4%
H
5.7
6.1
|
L
 -1.6%
H
5.7
6.3
|
L
 -17.6%
H
5.6
7.2
|
L
 -0.9%
H
5.3
7.6
|
L
 74.6%
H
3.0
9.8
|
L
 329.3%
H
1.0
9.8
|
L
 -38.3%
H
1.0
10.5
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
3,360.3
|
26.4
|
L
 -1.8%
H
25.8
27.9
|
L
 8.5%
H
24.2
27.9
|
L
 -13.0%
H
23.3
31.6
|
L
 -3.1%
H
23.3
31.7
|
L
 110.8%
H
12.2
31.7
|
L
 33.8%
H
6.5
31.7
|
L
 -26.8%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
217.8
|
3.8
|
L
 -5.5%
H
3.8
4.1
|
L
 -6.6%
H
3.8
4.3
|
L
 -19.2%
H
3.8
5.1
|
L
 -14.4%
H
3.4
5.1
|
L
 101.1%
H
1.8
5.5
|
L
 -23.4%
H
1.2
5.7
|
L
 -88.3%
H
1.2
33.0
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
3,989.0
|
12.3
|
L
 -2.7%
H
12.1
12.7
|
L
 7.9%
H
11.2
13.2
|
L
 8.8%
H
10.3
13.2
|
L
 114.5%
H
5.0
13.2
|
L
 154.9%
H
2.7
13.2
|
L
 146.2%
H
1.9
13.2
|
L
 -42.3%
H
1.9
22.1
|
L
H
1.9
71.9
|
| Absci Corp |
|
1,671.5
|
9.7
|
L
 -9.1%
H
9.5
10.6
|
L
 22.7%
H
7.9
11.3
|
L
 2.0%
H
7.8
11.3
|
L
 16.0%
H
6.7
12.1
|
L
 262.1%
H
2.2
12.1
|
L
 562.6%
H
1.1
12.1
|
L
 -12.4%
H
1.1
18.1
|
L
H
1.1
31.5
|
| Adma Biologics Inc |
|
2,172.7
|
9.7
|
L
 -1.1%
H
9.4
9.8
|
L
 12.7%
H
8.5
9.8
|
L
 -1.4%
H
8.5
9.9
|
L
 13.2%
H
8.2
10.4
|
L
 -39.5%
H
7.2
20.5
|
L
 176.4%
H
3.1
25.7
|
L
 682.3%
H
1.0
25.7
|
L
 33.8%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
4,451.1
|
27.9
|
L
 -0.6%
H
27.6
28.4
|
L
 4.5%
H
26.7
28.8
|
L
 7.3%
H
23.5
28.8
|
L
 -59.9%
H
20.9
91.2
|
L
 -50.0%
H
20.9
91.2
|
L
 37.5%
H
9.1
91.2
|
L
 -82.0%
H
9.1
158.5
|
L
H
9.1
285
|
| Agenus Inc |
|
379.4
|
8.4
|
L
 -3.5%
H
8.4
8.7
|
L
 17.3%
H
7.1
8.8
|
L
 3.8%
H
6.7
8.8
|
L
 176.3%
H
2.9
8.9
|
L
 82.6%
H
2.7
8.9
|
L
 -64.4%
H
1.4
196
|
L
 -92.9%
H
1.4
196
|
L
 -93.9%
H
1.4
196
|
| Change Agents Corp |
|
2.5
|
2.2
|
L
 7.3%
H
2
2.2
|
L
 12.1%
H
1.8
2.2
|
L
 -34.7%
H
1.8
4.7
|
L
 -69.4%
H
1.8
7.2
|
L
 -95.9%
H
1.8
55.4
|
L
 -99.2%
H
1.8
1350
|
L
 -99.9%
H
1.8
3450
|
L
H
1.8
40500
|
| Aldeyra Therapeutics Inc |
|
81.4
|
1.4
|
L
 -3.6%
H
1.3
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 -11.2%
H
1.3
1.6
|
L
 -34.2%
H
1.3
2.5
|
L
 -72.7%
H
1.1
5.9
|
L
 -78.0%
H
1.1
7.2
|
L
 -83.4%
H
1.1
12.0
|
L
 -81.6%
H
1.1
16.7
|
| Alector Inc |
|
225.5
|
2.0
|
L
 0.5%
H
2.0
2.0
|
L
 -1.0%
H
1.8
2.1
|
L
 -14.4%
H
1.8
2.8
|
L
 13.5%
H
1.4
2.8
|
L
 -36.5%
H
1.1
3.4
|
L
 -70.6%
H
0.9
8.9
|
L
 -91.9%
H
0.9
27
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
577.0
|
1.7
|
L
 -2.3%
H
1.7
1.7
|
L
 -2.9%
H
1.6
1.8
|
L
 -20.1%
H
1.6
2.2
|
L
 -20.5%
H
1.6
2.3
|
L
 42.7%
H
1.0
4.5
|
L
 -54.2%
H
0.9
5.8
|
L
 -93.5%
H
0.9
27.9
|
L
H
0.9
55
|
| Altimmune Inc |
|
620.5
|
3.2
|
L
 -6.5%
H
3.2
3.4
|
L
 -1.2%
H
3.2
3.4
|
L
 2.6%
H
3.0
3.6
|
L
 8.9%
H
2.7
3.6
|
L
 -19.4%
H
2.6
6.4
|
L
 22.2%
H
2.1
14.8
|
L
 -79.0%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
2,073.1
|
5.8
|
L
 -0.5%
H
5.7
5.9
|
L
 15.7%
H
5.1
6.0
|
L
 31.2%
H
4.7
6.0
|
L
 59.2%
H
3.0
6.0
|
L
 -27.5%
H
2.9
9.3
|
L
 -34.6%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
74.3
|
3.1
|
L
 -3.7%
H
3.1
3.2
|
L
 -2.5%
H
3.0
3.3
|
L
 -24.8%
H
3.0
4.3
|
L
 -29.1%
H
3.0
6.3
|
L
 -29.1%
H
3.0
11.9
|
L
 36.8%
H
0.4
12.9
|
L
 -86.1%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alx Oncology Holdings Inc |
|
203.3
|
1.5
|
L
 -8.1%
H
1.4
1.6
|
L
 -22.2%
H
1.4
1.9
|
L
 -27.9%
H
1.4
2.1
|
L
 -9.8%
H
1.4
2.4
|
L
 15.8%
H
1.1
2.7
|
L
 -70.8%
H
0.4
17.8
|
L
 -98.1%
H
0.4
79
|
L
H
0.4
117.5
|
| Amgen |
|
219,545.3
|
406.1
|
L
 -1.0%
H
404.3
415.8
|
L
 8.1%
H
374.5
415.8
|
L
 -7.6%
H
374.5
447.0
|
L
 17.8%
H
345.5
447.0
|
L
 42.0%
H
269.8
447.0
|
L
 51.7%
H
249.7
447.0
|
L
 90.1%
H
198.6
447.0
|
L
 131.2%
H
133.6
447.0
|
| AnaptysBio Inc |
|
1,517.8
|
50.8
|
L
 -5.8%
H
49.5
53.9
|
L
 -7.2%
H
49.5
56.0
|
L
 -12.1%
H
49.5
59.1
|
L
 -15.4%
H
49.5
70.9
|
L
 137.2%
H
20.7
73.3
|
L
 200.9%
H
12.2
73.3
|
L
 80.7%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,709.7
|
74.4
|
L
 -4.5%
H
74.2
78.9
|
L
 3.2%
H
72.2
79.4
|
L
 -1.2%
H
69.6
79.4
|
L
 -7.6%
H
69.6
87.2
|
L
 -22.4%
H
69.6
97
|
L
 27.2%
H
48.2
99.5
|
L
 147.4%
H
22.3
99.5
|
L
 11.4%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
95.6
|
2.8
|
L
 -1.4%
H
2.6
2.8
|
L
 2.2%
H
2.6
2.8
|
L
 -25.9%
H
2.6
3.9
|
L
 -0.7%
H
2.4
3.9
|
L
 -21.2%
H
2.3
5.5
|
L
 -17.9%
H
2.1
5.5
|
L
 -43.4%
H
2.1
6.5
|
L
 -6.8%
H
0.6
8.1
|
| Aptevo Therapeutics Inc |
|
3.4
|
1.9
|
L
 2.2%
H
1.8
1.9
|
L
 10.5%
H
1.7
1.9
|
L
 -29.5%
H
1.4
2.8
|
L
 -60.2%
H
1.4
4.9
|
L
 -93.8%
H
1.4
35.6
|
L
 -100.0%
H
1.4
287179.2
|
L
 -100.0%
H
1.4
12940587.7
|
L
 -100.0%
H
1.4
52102512
|
| AquaBounty Tech Inc |
|
5.4
|
1.0
|
L
 -4.6%
H
1.0
1.1
|
L
 -5.5%
H
1.0
1.2
|
L
 -20.6%
H
1.0
1.4
|
L
 3.0%
H
0.9
1.6
|
L
 -35.8%
H
0.8
3.0
|
L
 -78.7%
H
0.5
6.1
|
L
 -98.7%
H
0.5
90
|
L
H
0.5
610
|
| Arvinas Inc |
|
512.0
|
7.8
|
L
 -8.0%
H
7.8
8.6
|
L
 -5.2%
H
7.8
8.6
|
L
 -16.4%
H
7.8
9.7
|
L
 1.2%
H
7.6
9.7
|
L
 4.0%
H
7.0
14.5
|
L
 -65.5%
H
5.9
53.1
|
L
 -91.6%
H
5.9
97.3
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
9,458.4
|
67.0
|
L
 -6.8%
H
66.3
72.5
|
L
 -5.3%
H
64.5
72.5
|
L
 -23.1%
H
64.5
90.2
|
L
 -18.3%
H
64.5
95.5
|
L
 108.9%
H
31.5
95.5
|
L
 145.8%
H
9.6
95.5
|
L
 6.7%
H
9.6
95.5
|
L
 821.0%
H
1.2
95.5
|
| LeonaBio Inc |
|
55.5
|
5.9
|
L
 -2.6%
H
5.7
6.4
|
L
 -18.7%
H
5.7
7.7
|
L
 -23.3%
H
5.7
8.4
|
L
 -28.8%
H
5.7
10.1
|
L
 52.6%
H
3.6
14.2
|
L
 -70.3%
H
2.2
43.0
|
L
 -94.0%
H
2.2
166.5
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
2,182.0
|
16.4
|
L
 -1.6%
H
16.3
16.9
|
L
 1.7%
H
16.1
17.2
|
L
 -1.5%
H
15.9
17.2
|
L
 -6.5%
H
14.4
19.3
|
L
 25.5%
H
10.3
19.3
|
L
 96.4%
H
4.7
19.3
|
L
 -30.0%
H
4.1
34.0
|
L
 619.3%
H
2.0
34.0
|
| Aura Biosciences Inc |
|
624.3
|
6.0
|
L
 -6.7%
H
6.0
6.5
|
L
 -13.0%
H
6.0
7.0
|
L
 -22.8%
H
6.0
8.1
|
L
 -13.4%
H
6.0
8.4
|
L
 -2.3%
H
4.7
9.5
|
L
 -34.9%
H
4.3
12.4
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
488.3
|
25.0
|
L
 -5.7%
H
24.2
26.6
|
L
 -12.4%
H
24.2
29.2
|
L
 -33.6%
H
24.2
38.9
|
L
 -17.7%
H
24.2
39.5
|
L
 58.3%
H
14.4
39.5
|
L
 37.0%
H
1.4
61.1
|
L
 -65.9%
H
1.4
79.4
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
935.5
|
14.7
|
L
 -12.2%
H
14.6
16.6
|
L
 -15.4%
H
14.6
17.7
|
L
 -31.1%
H
14.6
22.4
|
L
 -24.4%
H
14.6
25
|
L
 85.7%
H
7.3
28
|
L
 -96.9%
H
6.6
1134.5
|
L
 -97.3%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
217.8
|
2.4
|
L
 -4.9%
H
2.3
2.5
|
L
 -3.7%
H
2.3
2.5
|
L
 -27.5%
H
2.3
3.7
|
L
 -7.5%
H
2.3
3.7
|
L
 -73.1%
H
2.3
10.4
|
L
 -65.9%
H
2.3
14.4
|
L
 -86.7%
H
2.3
23.7
|
L
 -28.4%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
10,133.1
|
193.5
|
L
 -4.8%
H
189.1
204.7
|
L
 -5.2%
H
189.1
216.5
|
L
 -6.9%
H
189.1
229.6
|
L
 -22.0%
H
189.1
252.6
|
L
 64.7%
H
115.3
260.2
|
L
 163.3%
H
55.0
260.2
|
L
 526.3%
H
20.6
260.2
|
L
 2383.3%
H
1.9
260.2
|
| Aziyo Biologics Inc (Class A) |
|
-
|
0.9
|
L
 7.4%
H
0.9
0.9
|
L
 8.8%
H
0.8
0.9
|
L
 -8.4%
H
0.8
1.1
|
L
 -13%
H
0.8
1.1
|
L
 -21.6%
H
0.5
1.4
|
L
 -38.3%
H
0.5
2.6
|
L
 -88.4%
H
0.5
9.0
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
18.8
|
9.7
|
L
 -3.9%
H
9.3
10.4
|
L
 -5.8%
H
8.5
11
|
L
 23.1%
H
7.4
12.2
|
L
 -14.0%
H
6.5
15.5
|
L
 -70.5%
H
3.0
49.6
|
L
 -93.3%
H
3.0
176
|
L
 -99.3%
H
3.0
1463.5
|
L
 -99.9%
H
3.0
17759.8
|
| Argen X SE (ADR) |
|
59,171.4
|
945.8
|
L
 -1.9%
H
934.2
974.6
|
L
 -3.5%
H
934.2
1003.8
|
L
 -9.0%
H
934.2
1072.8
|
L
 4.7%
H
826.4
1072.8
|
L
 27.8%
H
661.9
1072.8
|
L
 87.0%
H
327.7
1072.8
|
L
 204.6%
H
249.5
1072.8
|
L
H
17.3
1072.8
|
| BridgeBio Pharma Inc |
|
12,845.8
|
65.7
|
L
 -5.1%
H
64.9
70
|
L
 -3.9%
H
64.9
70
|
L
 -19.4%
H
64.9
82.5
|
L
 -4.7%
H
64.9
93.4
|
L
 27.5%
H
48.8
93.4
|
L
 141.0%
H
21.6
93.4
|
L
 31.6%
H
5.0
93.4
|
L
H
5.0
93.4
|
| BioCardia Inc |
|
15.9
|
1.1
|
L
H
1.0
1.1
|
L
 -14.6%
H
1.0
1.4
|
L
 4.0%
H
1.0
1.4
|
L
 8.3%
H
0.8
1.4
|
L
 -5.4%
H
0.8
1.8
|
L
 -82.8%
H
0.8
23.3
|
L
 -98.0%
H
0.8
55.1
|
L
 -99.4%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,189.9
|
8.6
|
L
 -2.4%
H
8.5
8.9
|
L
 5.0%
H
8.1
9.0
|
L
 -10.3%
H
8.0
10.2
|
L
 -6.2%
H
8.0
11.2
|
L
 8.3%
H
6
11.2
|
L
 16.6%
H
4.0
11.3
|
L
 -44.3%
H
4.0
20.0
|
L
 80.0%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
34.9
|
4.0
|
L
 -2.0%
H
4.0
4.2
|
L
 12.0%
H
3.5
4.4
|
L
 -1.5%
H
3.4
4.4
|
L
 33.2%
H
2.9
4.4
|
L
 -57.3%
H
2.6
14.7
|
L
 -100.0%
H
2.6
9540
|
L
 -100.0%
H
2.6
18526.5
|
L
 -100.0%
H
2.6
80097.7
|
| Black Diamond Therapeutics Inc |
|
109.2
|
1.9
|
L
 -4.0%
H
1.9
2.0
|
L
 -3.6%
H
1.9
2.0
|
L
 -14.0%
H
1.9
2.3
|
L
 18.0%
H
1.6
2.3
|
L
 -44.4%
H
1.6
4.9
|
L
 -44.3%
H
1.2
7.7
|
L
 -80.6%
H
1.2
10.0
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,517.1
|
24.4
|
L
 -6.0%
H
24.2
26.2
|
L
 5.0%
H
22.7
26.5
|
L
 -18.1%
H
22.7
31.5
|
L
 -31.4%
H
22.7
38.3
|
L
 -0.2%
H
20.2
38.3
|
L
 2.6%
H
13.5
49.5
|
L
 -74.5%
H
13.5
100.1
|
L
H
13
138.5
|
| BioVie Inc |
|
13.9
|
1.6
|
L
H
1.6
1.7
|
L
 -6.9%
H
1.6
1.8
|
L
 -16.4%
H
1.6
2.5
|
L
 -16.0%
H
0.8
3.8
|
L
 -13.8%
H
0.8
3.8
|
L
 -99.4%
H
0.8
582
|
L
 -99.8%
H
0.8
1438
|
L
 -100.0%
H
0.8
5625
|
| Biomarin pharma Inc - Registered Shares |
|
12,042.2
|
62.2
|
L
 -1.8%
H
61.6
64
|
L
 -3.5%
H
61.6
66.2
|
L
 -6.7%
H
61.6
67.7
|
L
 11.3%
H
55.7
71.0
|
L
 15.3%
H
49.3
71.0
|
L
 -28.1%
H
49.3
99.6
|
L
 -21.3%
H
49.3
117.8
|
L
 -36.2%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
20.0
|
1.7
|
L
 -6.6%
H
1.7
1.8
|
L
 9.0%
H
1.4
1.9
|
L
 41.7%
H
1.2
2.2
|
L
 47.8%
H
1
2.2
|
L
 -3.4%
H
1
2.2
|
L
 -41.8%
H
0.1
11.6
|
L
 -96.9%
H
0.1
62.8
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
342.9
|
9.8
|
L
 -10.2%
H
9.5
11.3
|
L
 -11.0%
H
9.5
11.6
|
L
 -27.1%
H
9.5
13.6
|
L
 -20.1%
H
9.5
14.3
|
L
 -27.2%
H
9.5
16.8
|
L
 222.3%
H
2.7
17.2
|
L
 -85.8%
H
1.9
68.3
|
L
 -97.0%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
9.8
|
1.2
|
L
 -0.8%
H
1.2
1.2
|
L
 9.1%
H
1.0
1.2
|
L
 5.3%
H
1.0
1.2
|
L
 -0.8%
H
1.0
1.3
|
L
 -40.9%
H
1.0
2.3
|
L
 -98.9%
H
1.0
173.5
|
L
 -100.0%
H
1.0
2500
|
L
 -100.0%
H
1.0
22532.5
|
| BioNTech SE (ADR) |
|
24,733.6
|
98.5
|
L
 -2.4%
H
98.3
101.3
|
L
 1.8%
H
95.3
102.2
|
L
 -15.5%
H
95.3
116.9
|
L
 9.2%
H
88.2
120.3
|
L
 -0.3%
H
79.5
124
|
L
 -5.9%
H
76.5
131.5
|
L
 -71.0%
H
76.5
374.6
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
376.4
|
2.2
|
L
 -11.2%
H
2.2
2.6
|
L
 -14.6%
H
2.2
2.7
|
L
 -29.1%
H
2.2
3.8
|
L
 -26.3%
H
2.2
3.8
|
L
 -3.9%
H
2
4.2
|
L
 -86.0%
H
1.0
26.4
|
L
 -81.8%
H
0.6
26.4
|
L
H
0.6
26.4
|
| Candel Therapeutics Inc |
|
863.9
|
11.3
|
L
 -4.7%
H
11.3
12.0
|
L
 1.5%
H
10.8
12.0
|
L
 -14.0%
H
9.9
14
|
L
 23.4%
H
9.0
14
|
L
 115.9%
H
4.4
14
|
L
 890.4%
H
0.7
14.6
|
L
 12.7%
H
0.7
14.6
|
L
H
0.7
14.8
|
| CalciMedica Inc |
|
12.2
|
1.8
|
L
 -4.3%
H
1.8
1.9
|
L
 -9.6%
H
1.8
2.1
|
L
 -37.4%
H
1.8
3
|
L
 -54.1%
H
1.8
5.8
|
L
 -88.9%
H
1.8
36
|
L
 -86.4%
H
1.8
41.9
|
L
 -99.3%
H
1.8
263.9
|
L
H
1.8
2651.6
|
| Tvardi Therapeutics Inc |
|
17.6
|
1.3
|
L
 -15.9%
H
1.3
1.6
|
L
 -25%
H
1.3
1.8
|
L
 -29.0%
H
1.3
2
|
L
 -50.8%
H
1.3
5.7
|
L
 -96.5%
H
1.3
43.7
|
L
 -97.8%
H
1.3
67.3
|
L
 -99.8%
H
1.3
681.5
|
L
 -99.5%
H
1.3
1067.3
|
| C4 Therapeutics Inc |
|
378.9
|
3.1
|
L
 -7.0%
H
2.9
3.3
|
L
 -10.2%
H
2.9
3.6
|
L
 -23%
H
2.9
4.3
|
L
 -25.2%
H
2.9
5.2
|
L
 18.0%
H
1.7
5.2
|
L
 51.0%
H
1.1
11.9
|
L
 -93.8%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
221.7
|
2.3
|
L
 -6.0%
H
2.3
2.5
|
L
 -2.9%
H
2.3
2.5
|
L
 -10.7%
H
2.3
2.9
|
L
 13.0%
H
2.0
2.9
|
L
 63.6%
H
1.4
3.2
|
L
 138.8%
H
0.5
3.2
|
L
 -63.2%
H
0.5
7.5
|
L
 -65.4%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
90.3
|
1.0
|
L
 -3.1%
H
1.0
1.0
|
L
 -8.7%
H
1.0
1.1
|
L
 -5%
H
1.0
1.1
|
L
 -43.5%
H
0.9
1.8
|
L
 -33.6%
H
0.6
2.1
|
L
 -28.6%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Celldex Therapeutics Inc |
|
2,443.8
|
31.1
|
L
 -7.1%
H
30.4
33.6
|
L
 -19.2%
H
30.4
41.6
|
L
 -22.9%
H
30.4
42.1
|
L
 -6.9%
H
30.4
45.1
|
L
 25.2%
H
22.1
45.1
|
L
 22.3%
H
14.4
53.2
|
L
 -42.7%
H
14.4
57.2
|
L
 -44.2%
H
1.5
75.3
|
| Co-Diagnostics Inc |
|
7.7
|
1.1
|
L
 1.9%
H
1.1
1.1
|
L
 -3.5%
H
0.9
1.1
|
L
 -9.1%
H
0.9
1.3
|
L
 -64.7%
H
0.9
4.6
|
L
 -91.3%
H
0.9
46.5
|
L
 -96.5%
H
0.9
66.9
|
L
 -99.6%
H
0.9
327
|
L
H
0.9
929.7
|
| Z Squared Inc |
|
156.9
|
3.0
|
L
 6.1%
H
2.6
3.0
|
L
 28.1%
H
2.2
3.0
|
L
 -18.9%
H
2.1
4.6
|
L
 -79.9%
H
2.1
14.5
|
L
 -81.2%
H
2.1
21.4
|
L
 -84.2%
H
2.1
27.6
|
L
 -70.2%
H
2.1
242.6
|
L
H
2.1
242.6
|
| Cogent Biosciences Inc |
|
5,450.4
|
31.4
|
L
 -3.7%
H
30.9
32.9
|
L
 -4.1%
H
30.9
33.6
|
L
 -14.5%
H
30.9
37.7
|
L
 -12.4%
H
30.9
43.4
|
L
 151.1%
H
12.4
43.7
|
L
 213.5%
H
3.7
43.7
|
L
 256.5%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Coya Therapeutics Inc |
|
118.2
|
5.0
|
L
 -4.9%
H
4.9
5.3
|
L
 8.4%
H
4.5
5.4
|
L
 3.5%
H
4.3
5.4
|
L
 -4.7%
H
3.9
6.2
|
L
 -7.9%
H
3.7
7.8
|
L
 25.4%
H
3.2
10.7
|
L
H
3.2
10.7
|
L
H
3.2
10.7
|
| Caribou Biosciences Inc |
|
138.3
|
1.3
|
L
 -3.7%
H
1.3
1.4
|
L
 1.6%
H
1.3
1.4
|
L
 -22.3%
H
1.3
1.8
|
L
 -21.3%
H
1.3
2.1
|
L
 -33.2%
H
1.3
3.5
|
L
 -74.7%
H
0.7
8.3
|
L
 -94.7%
H
0.7
26.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
215.1
|
1.8
|
L
 -6.4%
H
1.7
1.9
|
L
 -4.3%
H
1.7
2.0
|
L
 -4.8%
H
1.7
2.3
|
L
 67.0%
H
1.0
2.3
|
L
 58.0%
H
0.9
2.3
|
L
 94.5%
H
0.7
3.1
|
L
 -57.5%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
2.3
|
1.0
|
L
 -5%
H
0.9
1.0
|
L
 -15.9%
H
0.9
1.2
|
L
 -39.9%
H
0.9
1.7
|
L
 -88.9%
H
0.9
11.4
|
L
 -97.2%
H
0.9
34.9
|
L
 -99.5%
H
0.9
349.8
|
L
 -100.0%
H
0.9
3400
|
L
 -100.0%
H
0.9
7440
|
| CorMedix Inc |
|
599.4
|
7.7
|
L
 -1.2%
H
7.6
8.2
|
L
 -0.9%
H
7.6
8.2
|
L
 -6.2%
H
7.6
8.7
|
L
 -12.8%
H
7.1
9.0
|
L
 -31.8%
H
6.1
13.0
|
L
 109.5%
H
2.6
17.4
|
L
 65.0%
H
2.6
17.4
|
L
 -46.6%
H
0.9
18.8
|
| CRISPR Therapeutics AG |
|
5,391.6
|
55.8
|
L
 -5.5%
H
54.7
59.5
|
L
 7.6%
H
51.8
60.7
|
L
 -6.3%
H
51.3
61.6
|
L
 2.6%
H
45.9
63.5
|
L
 -10.2%
H
44.1
78.5
|
L
 22.6%
H
30.0
91.1
|
L
 -52.7%
H
30.0
122.3
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
69.9
|
5.0
|
L
 -5.1%
H
5.0
5.3
|
L
 5.2%
H
4.6
5.6
|
L
 1.2%
H
4.6
5.6
|
L
 -19.7%
H
4.6
6.7
|
L
 -25.6%
H
4.6
8.3
|
L
 -7.0%
H
3.6
12.0
|
L
 -52.2%
H
3.6
12.0
|
L
 202.4%
H
1.6
17.9
|
| Cue Biopharma Inc |
|
230.4
|
31.7
|
L
 2.6%
H
29.9
35.2
|
L
 0.2%
H
23.8
41.5
|
L
 32.2%
H
22.6
41.5
|
L
 3.2%
H
22.6
45.5
|
L
 50.1%
H
5.0
45.5
|
L
 -53.8%
H
5.0
97.5
|
L
 -92.5%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
4.7
|
1.3
|
L
 17.9%
H
1.1
1.4
|
L
 25.7%
H
1.0
1.4
|
L
 -18.0%
H
1
2.3
|
L
 -58.5%
H
1
3.9
|
L
 -89.9%
H
1
14.6
|
L
 88.6%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
16.7
|
2.3
|
L
 -4.2%
H
2.2
2.4
|
L
 -7.7%
H
2.2
2.9
|
L
 5.6%
H
2.1
3.0
|
L
 51.0%
H
1.4
3.0
|
L
 -13.3%
H
1.4
3.6
|
L
 -38.0%
H
1.4
10.2
|
L
 -95.3%
H
1.4
52.8
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,904.1
|
13.8
|
L
 -7.0%
H
13.7
14.7
|
L
 -0.4%
H
13.7
15.6
|
L
 3.2%
H
12.7
15.9
|
L
 8.9%
H
10.6
15.9
|
L
 172.8%
H
4.9
15.9
|
L
 74.9%
H
2.3
15.9
|
L
 -57.4%
H
2.3
49.5
|
L
H
2.3
61.7
|
| DiaMedica Therapeutics Inc |
|
407.7
|
7.6
|
L
 -2.8%
H
7.3
7.8
|
L
 15.8%
H
6.5
7.8
|
L
 16.0%
H
6.2
7.8
|
L
 28.4%
H
5.8
8.5
|
L
 8.3%
H
5.2
10.4
|
L
 170%
H
1.9
10.4
|
L
 95.3%
H
1.1
10.4
|
L
 91.9%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,270.5
|
20.5
|
L
 -5.3%
H
20.3
21.5
|
L
 0.4%
H
19.4
21.8
|
L
 -17.9%
H
19.4
25.3
|
L
 -14.9%
H
19.4
27.3
|
L
 53.6%
H
12.8
27.3
|
L
 -7.6%
H
10.6
33.3
|
L
 -60.6%
H
10.6
56.1
|
L
H
10.6
93.9
|
| Bright Minds Biosciences Inc |
|
568.3
|
57.9
|
L
 -4.5%
H
56.5
60.4
|
L
 -3.8%
H
56.5
62.5
|
L
 -25.2%
H
56.5
82.5
|
L
 -8.8%
H
56.5
87
|
L
 13.3%
H
48.9
123.8
|
L
 3248.0%
H
0.9
123.8
|
L
 91.3%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
773.5
|
12.4
|
L
 -6.1%
H
12.1
13.2
|
L
 1.2%
H
12.1
13.3
|
L
 -17.6%
H
12.1
16.0
|
L
 -9.8%
H
11.4
16.1
|
L
 94.7%
H
5.3
17.3
|
L
 415%
H
2.0
17.3
|
L
 -17.7%
H
1.9
26.3
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
175.5
|
6.4
|
L
 -11.5%
H
6.3
7.2
|
L
 -3.8%
H
6.3
7.3
|
L
 -28.1%
H
6.3
8.8
|
L
 -10.2%
H
6.3
9.6
|
L
 30.9%
H
3.5
9.6
|
L
 1573.7%
H
0.3
19.4
|
L
 -50.2%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
3,030.9
|
16.2
|
L
 -5.3%
H
16.2
17.1
|
L
 -9.3%
H
16.2
18.4
|
L
 -37.8%
H
16.2
26.7
|
L
 -22.2%
H
16.2
27.3
|
L
 20.8%
H
11.9
27.3
|
L
 78.5%
H
6.4
47.5
|
L
 0.7%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
413.1
|
2.7
|
L
 -7.9%
H
2.7
3.1
|
L
 2.3%
H
2.6
3.1
|
L
 -13.5%
H
2.6
3.5
|
L
 -3.9%
H
2.5
3.8
|
L
 -10.3%
H
1.7
4.5
|
L
 -65.7%
H
0.9
11.7
|
L
 -95.4%
H
0.9
62.4
|
L
 -81.8%
H
0.9
100.0
|
| Eloxx Pharma |
|
53.1
|
15.4
|
L
 -7.7%
H
14.5
16.6
|
L
 -15.4%
H
14.5
19.0
|
L
 -26.4%
H
13.8
23
|
L
 11.2%
H
10
23.4
|
L
 279.4%
H
8.2
23.4
|
L
 207.6%
H
0
23.4
|
L
 -78.1%
H
0
75.6
|
L
 -90.1%
H
0
984
|
| Elicio Therapeutics Inc |
|
49.1
|
1.9
|
L
H
1.8
1.9
|
L
 -6.0%
H
1.7
2.0
|
L
 -38.5%
H
1.7
3.1
|
L
 -54.8%
H
1.7
5.4
|
L
 -83.2%
H
1.7
16
|
L
 -76.1%
H
1.7
16
|
L
 -98.2%
H
1.7
105.7
|
L
H
1.7
263
|
| Enliven Therapeutics Inc |
|
3,377.0
|
46.1
|
L
 -4.4%
H
45.7
48.0
|
L
 -13.6%
H
45.7
54.1
|
L
 -23.0%
H
45.7
62
|
L
 0.3%
H
45.0
62.3
|
L
 131.4%
H
14.8
62.3
|
L
 250.0%
H
9.8
62.3
|
L
 172.4%
H
3.9
62.3
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
719.1
|
12.5
|
L
 -11.9%
H
12.1
14.4
|
L
 -10.0%
H
12.1
14.7
|
L
 -27.6%
H
12.1
18.3
|
L
 2.8%
H
11.4
18.3
|
L
 439.7%
H
1.5
18.3
|
L
 374.2%
H
1.1
18.3
|
L
 -20.8%
H
1.1
20.9
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
11.2
|
0.6
|
L
 -1.5%
H
0.6
0.7
|
L
 -27.3%
H
0.6
0.9
|
L
 -56.5%
H
0.6
1.7
|
L
 3.2%
H
0.4
7.6
|
L
 -39.6%
H
0.4
7.6
|
L
 -56.2%
H
0.4
7.6
|
L
 -94.4%
H
0.4
11.5
|
L
 -99.1%
H
0.4
72.8
|
| Enochian Biosciences Inc |
|
-
|
2.1
|
L
 -4.0%
H
2.1
2.4
|
L
 -2.3%
H
2.1
2.7
|
L
 -0.9%
H
2.1
2.9
|
L
 -48.4%
H
1.9
4.8
|
L
 1237.5%
H
0.1
5.0
|
L
 568.8%
H
0.1
5.0
|
L
 -69.3%
H
0.1
13.8
|
L
 7%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
8.2
|
0.4
|
L
 -2.3%
H
0.4
0.4
|
L
 -6.7%
H
0.4
0.5
|
L
 13.5%
H
0.4
0.5
|
L
 55.6%
H
0.2
1.0
|
L
 -80.8%
H
0.2
2.8
|
L
 -72.4%
H
0.1
9.9
|
L
 -100.0%
H
0.1
1680
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
111.0
|
1.8
|
L
 -9.3%
H
1.7
1.9
|
L
 -14.6%
H
1.7
2.1
|
L
 -24.2%
H
1.7
2.7
|
L
 -38.8%
H
1.7
3.5
|
L
 20.7%
H
0.8
3.5
|
L
 121.5%
H
0.3
3.5
|
L
 -74.0%
H
0.3
7.1
|
L
H
0.3
27.1
|
| Evogene Ltd |
|
7.1
|
0.5
|
L
 -8.2%
H
0.4
0.5
|
L
 -15.1%
H
0.4
0.5
|
L
 -19.6%
H
0.4
0.6
|
L
 -10%
H
0.4
0.8
|
L
 -61.5%
H
0.4
1.5
|
L
 -92.9%
H
0.4
10.4
|
L
 -98.5%
H
0.4
29.9
|
L
 -99.3%
H
0.4
102.4
|
| Edgewise Therapeutics Inc |
|
4,458.2
|
41.1
|
L
 -7.8%
H
39.8
44.4
|
L
 -5.9%
H
39.8
48.5
|
L
 -7.1%
H
39.8
48.5
|
L
 12.5%
H
36.0
48.5
|
L
 171.9%
H
14.3
48.5
|
L
 585.3%
H
5.1
48.5
|
L
 106.0%
H
5.1
48.5
|
L
H
5.1
48.5
|
| Evaxion Biotech A/S (ADR) |
|
29.6
|
3.3
|
L
 0.3%
H
3.2
3.4
|
L
 7.9%
H
3
3.4
|
L
 -0.9%
H
2.9
3.6
|
L
 -4.1%
H
2.8
3.6
|
L
 7.5%
H
2.8
12.2
|
L
 -57.2%
H
0.8
13.6
|
L
 -95.9%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
291.2
|
2.4
|
L
 -5.8%
H
2.4
2.6
|
L
 3.4%
H
2.3
2.7
|
L
 4.3%
H
2.2
2.7
|
L
 13.0%
H
1.8
3.2
|
L
 140.6%
H
1.0
3.2
|
L
 15.2%
H
0.7
8.8
|
L
 -96.5%
H
0.7
70.3
|
L
 -31.4%
H
0.7
121.2
|
| 4D Molecular Therapeutics Inc |
|
828.7
|
15
|
L
 -5.5%
H
14.7
16.0
|
L
 10.1%
H
13.5
16.2
|
L
 -5.2%
H
12.9
16.3
|
L
 44.0%
H
9.4
16.9
|
L
 102.7%
H
7.0
16.9
|
L
 7.8%
H
2.2
36.3
|
L
 -57.3%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
368.6
|
10.5
|
L
 -4.5%
H
10.5
11.0
|
L
 -1.2%
H
10.4
11.3
|
L
 -6.9%
H
10.1
12.8
|
L
 10.3%
H
9.3
13.3
|
L
 21.2%
H
5.7
13.3
|
L
 40.3%
H
4.0
13.3
|
L
 20.4%
H
3.8
13.3
|
L
 417.7%
H
1.6
15.0
|
| Foghorn Therapeutics Inc |
|
229.8
|
3.9
|
L
 -8.7%
H
3.9
4.2
|
L
 -6.1%
H
3.9
4.3
|
L
 -45.3%
H
3.9
7.4
|
L
 -7.4%
H
3.9
7.6
|
L
 -22.3%
H
3.3
7.6
|
L
 -36.0%
H
2.7
10.2
|
L
 -73.0%
H
2.7
24.3
|
L
H
2.7
28.3
|
| First Wave BioPharma Inc |
|
6.0
|
3.9
|
L
 -0.8%
H
3.8
4.1
|
L
 27.8%
H
2.9
4.1
|
L
 8.1%
H
2.7
4.2
|
L
 -20.6%
H
2.6
5.1
|
L
 -22.7%
H
1.9
6.9
|
L
 -44.7%
H
0.4
14.5
|
L
 -100.0%
H
0.4
15234.1
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
408.4
|
4.1
|
L
 -2.2%
H
4
4.2
|
L
 8.6%
H
3.6
4.2
|
L
 10.1%
H
3.6
4.7
|
L
 44.6%
H
2.7
5.6
|
L
 -17.7%
H
2.0
7.1
|
L
 131.4%
H
0.7
7.1
|
L
 8%
H
0.7
7.1
|
L
 41.1%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
80.3
|
1.8
|
L
 -5.6%
H
1.8
2.0
|
L
 7.6%
H
1.7
2.0
|
L
 -8%
H
1.7
2.1
|
L
 -0.5%
H
1.6
2.4
|
L
 5.8%
H
1.5
4.3
|
L
 -44.9%
H
0.9
5.3
|
L
 -76.1%
H
0.9
9.7
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
10.8
|
0.9
|
L
H
0.9
0.9
|
L
 13.8%
H
0.8
1.0
|
L
 -11.7%
H
0.8
1
|
L
 -15.7%
H
0.7
1.2
|
L
 -52.9%
H
0.7
3.7
|
L
 -73.3%
H
0.7
5.5
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
796.7
|
1.2
|
L
 -5.3%
H
1.2
1.3
|
L
 -5.3%
H
1.2
1.3
|
L
 -18.4%
H
1.2
1.6
|
L
 -7.5%
H
1.2
1.7
|
L
 -6.8%
H
1.0
2.0
|
L
 -42.3%
H
1.0
5.3
|
L
 -12.7%
H
1.0
5.3
|
L
 -44.1%
H
0.8
7.0
|
| Gilead Sciences |
|
187,692.0
|
151.4
|
L
 -0.9%
H
150.1
154.2
|
L
 3.5%
H
146.1
154.2
|
L
 3.6%
H
142.9
154.2
|
L
 21.2%
H
123.7
154.2
|
L
 34.6%
H
108.5
157.3
|
L
 101.8%
H
62.1
157.3
|
L
 112.1%
H
57.2
157.3
|
L
 85.7%
H
56.6
157.3
|
| Greenwich LifeSciences Inc |
|
257.0
|
17.5
|
L
 -10.1%
H
17.1
19.4
|
L
 8.8%
H
15.4
20.3
|
L
 5.0%
H
14.3
20.3
|
L
 -26.3%
H
12.5
24.6
|
L
 48.4%
H
7.8
34.1
|
L
 98.8%
H
7.6
34.1
|
L
 -59.9%
H
6.8
45.2
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,014.4
|
11.9
|
L
 -5.6%
H
11.7
12.6
|
L
 -8.5%
H
11.7
13.0
|
L
 -16.9%
H
11.7
15
|
L
 -36.3%
H
11.7
25.2
|
L
 82.1%
H
6.3
25.8
|
L
 98.2%
H
2.4
25.8
|
L
 -51.4%
H
2.4
27.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
3.5
|
0.4
|
L
 5.6%
H
0.4
0.4
|
L
 -9.5%
H
0.4
0.4
|
L
 -41.5%
H
0.4
0.9
|
L
 -71.2%
H
0.4
1.4
|
L
 -97.7%
H
0.4
17.5
|
L
 -99.8%
H
0.4
276.8
|
L
 -100.0%
H
0.4
2103.8
|
L
 -100.0%
H
0.4
379518072.3
|
| GRI Bio Inc |
|
4.7
|
2.2
|
L
 4.9%
H
2.0
2.2
|
L
 18.1%
H
1.7
2.2
|
L
 30.3%
H
1.7
3.4
|
L
 15.0%
H
1.4
3.4
|
L
 -96.2%
H
1.4
64.1
|
L
 -100.0%
H
1.4
77102.5
|
L
 -100.0%
H
1.4
11097548.5
|
L
H
1.4
13462627.3
|
| Graphite Bio Inc |
|
219.0
|
3.8
|
L
 -9.0%
H
3.7
4.1
|
L
 -11.1%
H
3.7
4.3
|
L
 -19.7%
H
3.7
6.0
|
L
 -35.4%
H
3.7
6.7
|
L
 -90.9%
H
3.7
50.4
|
L
 -96.8%
H
3.7
413
|
L
 -99.5%
H
3.7
847.7
|
L
H
3.7
1666
|
| Galapagos NV (ADR) |
|
2,024.4
|
30.7
|
L
 1.8%
H
30.7
32.4
|
L
 10.0%
H
27.2
32.4
|
L
 6.7%
H
26.6
32.4
|
L
 6.2%
H
25.7
32.4
|
L
 -8.8%
H
25.7
37.8
|
L
 -12.9%
H
22.4
42.5
|
L
 -43.1%
H
22.4
72.1
|
L
 -55.6%
H
22.4
274.0
|
| Genmab (ADR) |
|
21,367.9
|
34.8
|
L
 -1.3%
H
34.6
35.7
|
L
 1.8%
H
34.1
35.7
|
L
 3.9%
H
32.2
35.7
|
L
 35.7%
H
25.3
35.7
|
L
 21.5%
H
23.6
35.7
|
L
 -3.7%
H
17.2
36.7
|
L
 -21.1%
H
17.2
47.5
|
L
 101.1%
H
12.1
49.1
|
| Halozyme Therapeutics Inc |
|
12,761.7
|
112.4
|
L
 -2.3%
H
112.2
116.8
|
L
 5.8%
H
105.5
116.8
|
L
 4.0%
H
103.5
116.8
|
L
 63.0%
H
68.9
116.8
|
L
 43.6%
H
61.2
116.8
|
L
 184.2%
H
32.8
116.8
|
L
 171.4%
H
29.9
116.8
|
L
 806.8%
H
8.2
116.8
|
| HCW Biologics Inc |
|
3.0
|
1.7
|
L
 -8.3%
H
1.6
1.8
|
L
 -19.0%
H
1.6
2.2
|
L
 -23.9%
H
1.6
3.8
|
L
 -76.2%
H
1.6
7.1
|
L
 -93.2%
H
1.5
29.3
|
L
 -100.0%
H
1.5
24192
|
L
 -100.0%
H
1.5
67680
|
L
H
1.5
74640
|
| Hillstream BioPharma Inc |
|
26.3
|
2.2
|
L
 -8.6%
H
2.2
2.4
|
L
 9.8%
H
1.9
2.5
|
L
 2.3%
H
1.9
2.5
|
L
 -30.2%
H
1.8
3.3
|
L
 -23.0%
H
1.8
6.9
|
L
 -61.1%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
55.1
|
0.3
|
L
 -3.3%
H
0.3
0.3
|
L
 -6.5%
H
0.3
0.3
|
L
 -9.4%
H
0.3
0.4
|
L
 -32.6%
H
0.3
0.5
|
L
 -77.7%
H
0.3
1.6
|
L
 -71.3%
H
0.3
3.9
|
L
 -97.7%
H
0.3
12.9
|
L
 -98.4%
H
0.3
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
31.4
|
3.9
|
L
 4.9%
H
3.7
4.3
|
L
 12.1%
H
3.4
4.3
|
L
 12.8%
H
2.9
4.3
|
L
 6.0%
H
2.7
4.4
|
L
 -79.0%
H
2.1
19.4
|
L
 -95.2%
H
2.1
97.5
|
L
 -96.1%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
158.3
|
0.6
|
L
 -1.7%
H
0.6
0.6
|
L
 3.6%
H
0.6
0.6
|
L
 -10.9%
H
0.5
0.7
|
L
 -32.1%
H
0.5
0.9
|
L
 -67.8%
H
0.5
2.6
|
L
 -80.2%
H
0.5
10.0
|
L
 -95.7%
H
0.5
13.7
|
L
H
0.5
17.5
|
| Immucell Corp |
|
90.7
|
10.0
|
L
H
9.9
10.1
|
L
 4.3%
H
9.5
10.2
|
L
 -0.7%
H
9.5
10.3
|
L
 2.6%
H
9.5
12.1
|
L
 59.8%
H
4.5
12.1
|
L
 84.3%
H
3.3
12.1
|
L
 1.6%
H
3.3
12.1
|
L
 22.6%
H
3.3
13.2
|
| InflaRx N.V. |
|
288.8
|
2.0
|
L
 -5.8%
H
2.0
2.1
|
L
 -3.0%
H
2.0
2.2
|
L
 -6.7%
H
2.0
2.5
|
L
 3.2%
H
1.6
2.6
|
L
 45.2%
H
0.8
3.0
|
L
 -37.0%
H
0.7
3.1
|
L
 -28.5%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
54.9
|
4.8
|
L
 -0.2%
H
4.8
5.0
|
L
 -1.6%
H
4.6
5.3
|
L
 -12.2%
H
4.6
5.7
|
L
 -19.2%
H
4.6
6.3
|
L
 -39.5%
H
3.9
9.1
|
L
 -91.2%
H
3.9
59.3
|
L
 -96.9%
H
3.9
210
|
L
H
3.9
451.3
|
| Immunome Inc |
|
2,753.1
|
24.2
|
L
 -5.9%
H
24.0
25.9
|
L
 1.2%
H
23.4
25.9
|
L
 -15.0%
H
23.4
29.7
|
L
 26.4%
H
19
30.1
|
L
 148.1%
H
9.9
30.1
|
L
 234.8%
H
5.2
31.0
|
L
 5.1%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
8.2
|
1.5
|
L
 -2.7%
H
1.4
1.6
|
L
 5%
H
1.3
1.6
|
L
 -10.4%
H
1.3
1.8
|
L
 -18.3%
H
1.3
2.2
|
L
 -71.5%
H
1.3
5.6
|
L
 -90.7%
H
1.3
54.8
|
L
 -99.4%
H
1.3
236.3
|
L
 -100.0%
H
1.3
4095
|
| Immunovant Inc |
|
7,134.3
|
34.5
|
L
 -7.4%
H
33.6
37
|
L
 -5.8%
H
33.6
38.4
|
L
 -22.2%
H
33.6
44.5
|
L
 -9.3%
H
33.6
45.4
|
L
 121.6%
H
14.9
45.4
|
L
 69.4%
H
12.7
45.6
|
L
 295.2%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
10.8
|
1.1
|
L
 -3.5%
H
1.1
1.2
|
L
 4.8%
H
1.0
1.2
|
L
 -14.1%
H
1.0
1.3
|
L
 -24.7%
H
0.9
1.5
|
L
 -47.9%
H
0.9
2.7
|
L
 -10.6%
H
0.1
4.2
|
L
 -84.3%
H
0.1
9.4
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
4,753.4
|
100.3
|
L
 -9.3%
H
98.6
110.9
|
L
 -5%
H
98.6
117.1
|
L
 -3.2%
H
94
131.0
|
L
 7.5%
H
77.5
131.0
|
L
 270.0%
H
27.1
155.3
|
L
 415.0%
H
10.8
155.3
|
L
 174.5%
H
7.7
155.3
|
L
H
7.7
155.3
|
| MiNK Therapeutics Inc |
|
63.0
|
12.4
|
L
 2.0%
H
11.7
12.5
|
L
 8.2%
H
11.3
12.7
|
L
 1.2%
H
10.8
12.7
|
L
 0.8%
H
10.2
12.7
|
L
 -24.2%
H
8.5
16.9
|
L
 -5%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
55.5
|
2
|
L
 -7.4%
H
2.0
2.2
|
L
 -11.5%
H
2.0
2.4
|
L
 -13.8%
H
2.0
2.6
|
L
 39.9%
H
1.3
2.6
|
L
 1.0%
H
1.1
2.6
|
L
 -70.9%
H
1.1
14.7
|
L
 -89.6%
H
1.1
21.7
|
L
H
1.1
30.4
|
| Iovance Biotherapeutics Inc |
|
4,615.8
|
10.2
|
L
 -4.2%
H
10.1
10.8
|
L
 8.9%
H
9.4
11.0
|
L
 22.9%
H
7.7
11.0
|
L
 151.0%
H
3.8
11.0
|
L
 380.7%
H
1.8
11.0
|
L
 109.2%
H
1.6
18.3
|
L
 -59.2%
H
1.6
28.0
|
L
 24.3%
H
1.6
54.2
|
| MindWalk Holdings Corp |
|
65.5
|
1.4
|
L
 -6.1%
H
1.4
1.5
|
L
 19.8%
H
1.1
1.5
|
L
 -1.4%
H
1.1
1.5
|
L
 -7.3%
H
1.1
1.7
|
L
 -30.9%
H
1.0
3.0
|
L
 -29.4%
H
0.3
3.3
|
L
 -79.3%
H
0.3
6.9
|
L
 6850%
H
0.3
33.3
|
| Century Therapeutics Inc |
|
318.7
|
1.8
|
L
 -6.9%
H
1.8
1.9
|
L
 -11.1%
H
1.8
2.1
|
L
 -15.0%
H
1.8
2.3
|
L
 -23.5%
H
1.8
2.6
|
L
 266.7%
H
0.4
3.0
|
L
 -18.9%
H
0.3
5.5
|
L
 -91.6%
H
0.3
25.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,537.4
|
66.1
|
L
 -3.5%
H
65.3
68.9
|
L
 -1.8%
H
65.3
72.1
|
L
 -17.2%
H
65.3
83.6
|
L
 -6.7%
H
65.3
83.6
|
L
 7.5%
H
40
99.5
|
L
 35.1%
H
25.6
99.5
|
L
 48.5%
H
11.6
99.5
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
271.2
|
0.9
|
L
 -4.2%
H
0.9
1.0
|
L
 10.8%
H
0.7
1.1
|
L
 -8%
H
0.7
1.1
|
L
 1.1%
H
0.5
1.1
|
L
 -24.6%
H
0.5
3.1
|
L
 -43.6%
H
0.4
5.2
|
L
 -98.0%
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,624.3
|
31.5
|
L
 -2.7%
H
31.1
32.4
|
L
 -0.8%
H
31.1
32.8
|
L
 -14.5%
H
31.1
38.0
|
L
 7.5%
H
29.1
38.0
|
L
 -5.1%
H
27.6
40.7
|
L
 -39.4%
H
23.2
77.0
|
L
 -12.3%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
39.8
|
0.3
|
L
 -3.6%
H
0.3
0.3
|
L
 -18.2%
H
0.3
0.3
|
L
 -30.8%
H
0.3
0.4
|
L
 -29.0%
H
0.3
0.5
|
L
 -84.2%
H
0.3
3.5
|
L
 -86.4%
H
0.3
3.5
|
L
 -92.9%
H
0.3
5
|
L
 -90.9%
H
0.3
8.0
|
| Inventiva (ADR) |
|
815.0
|
3.5
|
L
 -5.5%
H
3.4
3.6
|
L
 -10.6%
H
3.4
3.9
|
L
 -26.3%
H
3.4
5.1
|
L
 -1.7%
H
3.4
5.1
|
L
 -42.7%
H
3.4
8.0
|
L
 -21.2%
H
1.5
8.0
|
L
 -76.0%
H
1.5
15.8
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
1,010.0
|
16.5
|
L
 -5.4%
H
16.3
17.5
|
L
 0.5%
H
16.0
17.5
|
L
 -5%
H
16.0
20.3
|
L
 15.2%
H
14.3
20.3
|
L
 -29.7%
H
12.1
35.3
|
L
 72.1%
H
5.7
71.7
|
L
 -30%
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
19.0
|
0.6
|
L
 -8.1%
H
0.6
0.7
|
L
H
0.6
0.7
|
L
 -20.8%
H
0.6
0.7
|
L
 14%
H
0.3
1.0
|
L
 -77.6%
H
0.3
2.7
|
L
 -26.9%
H
0.3
31.0
|
L
 -94.4%
H
0.3
31.0
|
L
H
0.3
31.0
|
| Kamada Ltd |
|
506.1
|
8.8
|
L
 -1.1%
H
8.7
8.9
|
L
 8.4%
H
8.1
9.0
|
L
 6.4%
H
7.9
9.0
|
L
 22.0%
H
6.9
9.0
|
L
 25.5%
H
6.5
9.4
|
L
 69.6%
H
4.1
9.4
|
L
 65.2%
H
3.7
9.4
|
L
 77.2%
H
3.7
13.3
|
| Kodiak Sciences Inc |
|
1,981.0
|
31.5
|
L
 -6.8%
H
30.8
34.5
|
L
 -4.5%
H
30.8
34.5
|
L
 -17.8%
H
30.8
40.1
|
L
 -14.0%
H
30.8
46.9
|
L
 110.0%
H
10.9
47.8
|
L
 1516.4%
H
1.4
47.8
|
L
 -69.3%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
10,115.4
|
341.8
|
L
 -2.6%
H
337.6
353.8
|
L
 1.5%
H
332.4
353.8
|
L
 -1.4%
H
331.8
373.3
|
L
 -0.5%
H
297.0
382.5
|
L
 106.6%
H
158.1
382.5
|
L
 196.8%
H
94.0
382.5
|
L
 516.0%
H
38.9
382.5
|
L
H
8.0
382.5
|
| TuHURA Biosciences Inc |
|
130.6
|
2.1
|
L
 -3.8%
H
2.0
2.1
|
L
 1.0%
H
2.0
2.2
|
L
 2.5%
H
2.0
2.2
|
L
 -24.4%
H
2.0
2.8
|
L
 -19.6%
H
0.4
3.4
|
L
 -98.7%
H
0.2
160.5
|
L
 -99.9%
H
0.2
2222.5
|
L
 -100.0%
H
0.2
115500
|
| Kura Oncology Inc |
|
982.1
|
11.0
|
L
 -5.9%
H
10.8
11.8
|
L
 -2.3%
H
10.8
12.2
|
L
 -7.2%
H
10.8
13.9
|
L
 6.6%
H
8.8
13.9
|
L
 36.5%
H
7.4
13.9
|
L
 24.6%
H
5.4
24.2
|
L
 -45.3%
H
5.4
24.2
|
L
 56.6%
H
4
43
|
| Kymera Therapeutics Inc |
|
9,601.4
|
115.5
|
L
 -5.4%
H
112.9
123
|
L
 2.1%
H
112.9
123
|
L
 -3.6%
H
110.3
127.9
|
L
 16.1%
H
94.6
130.1
|
L
 126.4%
H
50.4
130.1
|
L
 559.8%
H
9.6
130.1
|
L
 85.2%
H
9.6
130.1
|
L
H
9.6
130.1
|
| Kazia Therapeutics Ltd (ADR) |
|
149.3
|
9.6
|
L
 -12.1%
H
9.2
11.0
|
L
 -7.3%
H
9.2
11.3
|
L
 -28.4%
H
9.2
17.2
|
L
 -31.4%
H
9.2
17.2
|
L
 27.7%
H
4.9
17.4
|
L
 -81.4%
H
2.9
79
|
L
 -98.3%
H
2.9
614
|
L
 -97.6%
H
2.9
792.5
|
| Longeveron Inc (Class A) |
|
8.3
|
2.6
|
L
 -4.4%
H
2.5
2.8
|
L
 -62.1%
H
2.3
7.2
|
L
 -69.2%
H
2.3
8.7
|
L
 -67.5%
H
2.3
8.9
|
L
 -66.2%
H
2.3
12.3
|
L
 -98.8%
H
2.3
429.8
|
L
 -99.3%
H
2.3
4500
|
L
H
2.3
4500
|
| Lixte biotech Holdings Inc |
|
64.4
|
3.5
|
L
 -7.9%
H
3.4
3.8
|
L
 4.8%
H
3.3
4.0
|
L
 -18.1%
H
3.2
4.6
|
L
 -52.9%
H
3.1
8.4
|
L
 -35.1%
H
2.4
8.4
|
L
 89.2%
H
0.6
8.4
|
L
 -83.0%
H
0.6
49.5
|
L
 -70.7%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
389.0
|
3.6
|
L
 -3.2%
H
3.5
4.0
|
L
 62.6%
H
2.3
4.0
|
L
 154.2%
H
1.5
4.0
|
L
 387.8%
H
0.6
4.0
|
L
 1064.5%
H
0.3
4.0
|
L
 167.4%
H
0.2
5
|
L
 -88.9%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
401.0
|
3.9
|
L
 1.1%
H
3.7
3.9
|
L
 -1.3%
H
3.7
4.1
|
L
 -7.7%
H
3.7
4.2
|
L
 5.5%
H
2.9
4.5
|
L
 -13.8%
H
2.7
6.4
|
L
 -8.1%
H
1.6
13.7
|
L
 -68.2%
H
1.5
13.7
|
L
 -90.5%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
258.0
|
10.5
|
L
 -5.6%
H
10.3
11.1
|
L
 -3.5%
H
10.3
11.2
|
L
 -32.2%
H
10.3
15.7
|
L
 -12.0%
H
10.3
17.2
|
L
 -20.1%
H
10.3
45
|
L
 -63.9%
H
7.7
65.1
|
L
 -95.3%
H
7.7
309.9
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
88.0
|
1.3
|
L
 -5.1%
H
1.3
1.4
|
L
 -9.0%
H
1.3
1.5
|
L
 -12.7%
H
1.3
1.6
|
L
 -29.2%
H
1.3
2.0
|
L
 -60.4%
H
1.3
3.7
|
L
 -1.5%
H
0.8
4.7
|
L
 -82.2%
H
0.8
9.6
|
L
 -99.3%
H
0.8
234.9
|
| Seres Therapeutics Inc |
|
38.1
|
3.8
|
L
 -5.7%
H
3.7
4.2
|
L
 -17.6%
H
3.7
4.8
|
L
 -16.9%
H
3.7
6.0
|
L
 -42.6%
H
3.7
8.3
|
L
 -77.1%
H
3.7
30.0
|
L
 45.2%
H
0.4
30.0
|
L
 -46.0%
H
0.4
30.0
|
L
 -72.0%
H
0.4
38.5
|
| Magenta Therapeutics Inc |
|
-
|
93.4
|
L
 -5.0%
H
89.8
98.5
|
L
 -10.8%
H
89.8
107
|
L
 -15.9%
H
89.8
113.9
|
L
 7.0%
H
84.6
117.9
|
L
 147.5%
H
32.2
117.9
|
L
 374.6%
H
16.6
117.9
|
L
 -20.4%
H
5.1
135.8
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
1,128.5
|
11.8
|
L
 -4.9%
H
11.5
12.5
|
L
 -7.9%
H
11.5
13.5
|
L
 -18.1%
H
11.5
15.3
|
L
 2.4%
H
11.3
15.4
|
L
 45.2%
H
6.6
15.4
|
L
 137.4%
H
3.5
15.4
|
L
 -12.1%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,377.3
|
26.9
|
L
 -8.5%
H
26.6
29.8
|
L
 -7.0%
H
26.6
29.8
|
L
 4.8%
H
25.0
32.0
|
L
 6.0%
H
24.6
32.0
|
L
 -30.7%
H
22.3
47.7
|
L
 150.4%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
599.9
|
89.4
|
L
 -7.5%
H
87.6
96.8
|
L
 -14.3%
H
87.6
105.5
|
L
 -17.0%
H
87.6
121.0
|
L
 30.2%
H
68.2
124.8
|
L
 40.4%
H
50.1
124.8
|
L
 2929.8%
H
1.4
124.8
|
L
 249.1%
H
1.4
124.8
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
20.7
|
1.2
|
L
 1.6%
H
1.2
1.3
|
L
 6.0%
H
1.1
1.3
|
L
 -10.8%
H
1.1
1.6
|
L
 -9.5%
H
1.1
1.7
|
L
 37.8%
H
0.8
2.5
|
L
 -74.8%
H
0.8
6.2
|
L
 -92.9%
H
0.7
19
|
L
 -98.3%
H
0.7
135.5
|
| Moderna |
|
72,704.8
|
182.1
|
L
 -0.3%
H
181.3
192.3
|
L
 26.7%
H
142.3
192.3
|
L
 25.5%
H
130
192.3
|
L
 206.9%
H
52.7
192.3
|
L
 585.7%
H
22.3
192.3
|
L
 82.1%
H
22.3
192.3
|
L
 -58.7%
H
22.3
458.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
1,098.1
|
7.4
|
L
 -1.2%
H
7.1
7.5
|
L
 7.1%
H
6.8
7.5
|
L
 -14.7%
H
6.5
9.4
|
L
 40.4%
H
5.2
9.4
|
L
 168%
H
2.5
9.4
|
L
 -23.2%
H
1.7
11.6
|
L
 -84.9%
H
1.7
50.2
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
122.8
|
1.2
|
L
 -4.0%
H
1.2
1.2
|
L
H
1.2
1.3
|
L
 -13.8%
H
1.1
1.4
|
L
 0.9%
H
1.0
1.5
|
L
 -23.2%
H
0.6
1.9
|
L
 -61.7%
H
0.6
5.5
|
L
 -91.5%
H
0.6
14.3
|
L
H
0.6
17.4
|
| Mainz Biomed N.V. |
|
111.0
|
1.3
|
L
H
1.3
1.4
|
L
 0.8%
H
1.3
1.4
|
L
 1.5%
H
1.3
1.7
|
L
 -14.3%
H
1.0
1.9
|
L
 -19.0%
H
0.3
4.9
|
L
 -98.9%
H
0.3
135.7
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
1,985.5
|
15.3
|
L
 -4.0%
H
15.2
15.8
|
L
 3.7%
H
14.2
16.0
|
L
 -10.1%
H
14.2
18.3
|
L
 -1.4%
H
13.1
19.4
|
L
 -9.3%
H
13.1
21.5
|
L
 1133.1%
H
1.0
22
|
L
 153.1%
H
1.0
22
|
L
 236.8%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
164.7
|
4.3
|
L
 0.9%
H
4.3
4.3
|
L
 2.4%
H
3.8
4.7
|
L
 -2.3%
H
3.8
4.7
|
L
 8.9%
H
3.7
4.7
|
L
 17.2%
H
3.5
5.4
|
L
 -8.5%
H
3.3
12.7
|
L
 -77.7%
H
3.3
32.0
|
L
 -82.7%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
54.3
|
0.3
|
L
 6.3%
H
0.3
0.4
|
L
 21.4%
H
0.3
0.4
|
L
 17.2%
H
0.2
0.4
|
L
 6.3%
H
0.2
0.4
|
L
 -81.6%
H
0.2
2.4
|
L
 -74.8%
H
0.2
5.0
|
L
 -86.6%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
120.9
|
1.0
|
L
 -5%
H
1.0
1.0
|
L
 6.7%
H
0.9
1.0
|
L
 -1.0%
H
0.9
1.1
|
L
 -58.9%
H
0.8
2.4
|
L
 33.8%
H
0.7
4.3
|
L
 -70.2%
H
0.6
4.3
|
L
 -86.4%
H
0.6
7.1
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
14,179.0
|
139.5
|
L
 -1.9%
H
139.3
142.2
|
L
 -7.0%
H
139.3
152.6
|
L
 -8.6%
H
139.3
160.4
|
L
 -13.7%
H
139.3
186.1
|
L
 -4.9%
H
122.1
186.1
|
L
 22.6%
H
84.2
186.1
|
L
 48.0%
H
71.9
186.1
|
L
 157.6%
H
37.3
186.1
|
| Nkarta Inc |
|
197.7
|
2.8
|
L
 -6.4%
H
2.6
3.0
|
L
 -4.2%
H
2.6
3.1
|
L
 3.8%
H
2.5
3.3
|
L
 -1.1%
H
2.0
3.7
|
L
 31.4%
H
1.7
3.7
|
L
 71.4%
H
1.3
16.2
|
L
 -90.9%
H
1.3
31.5
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
30.9
|
L
 -8.0%
H
30.1
33.5
|
L
 -8.2%
H
30.1
35.6
|
L
 -19.9%
H
30.1
42.0
|
L
 -4.1%
H
29.7
43.7
|
L
 82.2%
H
15.9
43.7
|
L
 124.9%
H
12.7
43.7
|
L
 -79.5%
H
7.5
160.3
|
L
 -89.7%
H
7.5
399.4
|
| MetaVia Inc |
|
10.7
|
1.6
|
L
 -3.0%
H
1.6
1.7
|
L
 3.2%
H
1.5
1.7
|
L
 11.6%
H
1.4
1.9
|
L
 3.8%
H
1.4
2.6
|
L
 -85.6%
H
1.0
14.9
|
L
 -96.4%
H
1.0
74.3
|
L
 -100.0%
H
1.0
10861.0
|
L
 -100.0%
H
1.0
1424940
|
| Nurix Therapeutics Inc |
|
2,478.3
|
23.9
|
L
 -7.0%
H
23.9
25.6
|
L
 -3.8%
H
23.9
26.4
|
L
 -10.6%
H
23.9
27.5
|
L
 28.0%
H
18.4
28.2
|
L
 183.3%
H
8.2
28.2
|
L
 169.8%
H
4.2
29.6
|
L
 -31.7%
H
4.2
36.2
|
L
H
4.2
52.4
|
| Intellia Therapeutics Inc |
|
1,727.8
|
12.3
|
L
 -2.8%
H
12.0
12.9
|
L
 8.5%
H
11.4
13.0
|
L
 -4.0%
H
11.2
13.7
|
L
 -21.7%
H
10.2
18.5
|
L
 -28.6%
H
8.0
28.3
|
L
 -61.9%
H
5.9
34.9
|
L
 -91.7%
H
5.9
155.6
|
L
 -31.5%
H
5.9
202.7
|
| Natera Inc |
|
56,330.1
|
390.8
|
L
 0.0%
H
385.0
394.9
|
L
 11.4%
H
343.3
394.9
|
L
 17.7%
H
316
394.9
|
L
 70.8%
H
224.4
394.9
|
L
 118.1%
H
157.4
394.9
|
L
 752.9%
H
36.9
394.9
|
L
 210.9%
H
26.1
394.9
|
L
 3545.4%
H
7.4
394.9
|
| Novavax Inc |
|
1,740.2
|
10.6
|
L
 -2.6%
H
10.5
10.9
|
L
 14.3%
H
9.2
11.1
|
L
 18.0%
H
8.3
11.1
|
L
 17.2%
H
7.2
11.1
|
L
 18.9%
H
6.2
12.0
|
L
 48.0%
H
3.5
23.9
|
L
 -95.5%
H
3.5
260.7
|
L
 -75.5%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
5.5
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 0.8%
H
1.3
1.4
|
L
 -13.8%
H
1.3
1.9
|
L
 -28.4%
H
1.2
2.0
|
L
 -67.3%
H
1.2
7.2
|
L
 -100.0%
H
1.2
810296.8
|
L
 -100.0%
H
1.2
3319720
|
L
H
1.2
32000000
|
| Insight Molecular Diagnostics Inc |
|
128.0
|
3.9
|
L
 -5.6%
H
3.7
4.1
|
L
 -2.7%
H
3.5
4.3
|
L
 -9.9%
H
3.5
4.5
|
L
 -27.6%
H
3.5
6.1
|
L
 19.6%
H
2.4
8.5
|
L
 23.0%
H
1.9
8.5
|
L
 -95.1%
H
1.9
81.3
|
L
 -95.8%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
69.3
|
1.3
|
L
 -2.2%
H
1.3
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 -14.3%
H
1.3
1.7
|
L
 -15.9%
H
1.3
1.9
|
L
 -41.3%
H
1.3
3.2
|
L
 -33.7%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
86.7
|
0.7
|
L
 -4.2%
H
0.7
0.7
|
L
 -12.8%
H
0.7
0.8
|
L
 -19.1%
H
0.7
0.9
|
L
 -26.1%
H
0.7
1.1
|
L
 -47.7%
H
0.7
1.5
|
L
 -68.5%
H
0.3
2.3
|
L
 -68.7%
H
0.3
3.4
|
L
 -75.1%
H
0.3
8.5
|
| Traws Pharma Inc |
|
7.7
|
0.5
|
L
H
0.5
0.5
|
L
 -5.7%
H
0.5
0.6
|
L
 -5.7%
H
0.5
0.6
|
L
 -43.8%
H
0.4
0.9
|
L
 -73.8%
H
0.4
3.3
|
L
 -97.4%
H
0.4
27.5
|
L
 -99.7%
H
0.4
140
|
L
 -100.0%
H
0.4
21825
|
| VivoSim Labs Inc |
|
3.1
|
0.2
|
L
 -4.2%
H
0.2
0.2
|
L
 -14.8%
H
0.2
0.3
|
L
 -20.7%
H
0.2
0.3
|
L
 -79.7%
H
0.2
1.6
|
L
 -93.8%
H
0.2
4.1
|
L
 -98.6%
H
0.2
24.6
|
L
 -99.7%
H
0.2
88.3
|
L
 -100.0%
H
0.2
993.6
|
| Passage Bio Inc |
|
16.1
|
5
|
L
 1.0%
H
4.8
5.1
|
L
 4.8%
H
4.7
5.1
|
L
 12.6%
H
4.3
5.4
|
L
 -12.6%
H
3.3
6.3
|
L
 -33.7%
H
3.3
20
|
L
 -63.0%
H
3.3
35.8
|
L
 -97.7%
H
3.3
219.5
|
L
H
3.3
764.6
|
| Vaxcyte Inc |
|
8,407.5
|
56.5
|
L
 -4.3%
H
55.1
59.1
|
L
 -4.6%
H
55.1
61.5
|
L
 -9.8%
H
55.1
63.9
|
L
 8.4%
H
51.5
64.0
|
L
 68.8%
H
31.9
65
|
L
 7.7%
H
27.7
121.1
|
L
 117.1%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
188.4
|
2.7
|
L
 -8.7%
H
2.7
3.0
|
L
 -5.9%
H
2.7
3.0
|
L
 -13.4%
H
2.7
3.6
|
L
 48.6%
H
1.6
3.6
|
L
 28.3%
H
1.3
7.8
|
L
 -46.9%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
2,663.8
|
7.4
|
L
 -5.7%
H
7.2
8.0
|
L
 6.3%
H
6.9
8.0
|
L
 3.3%
H
6.5
8.0
|
L
 38.3%
H
4.8
8.0
|
L
 93.3%
H
3.0
8.0
|
L
 431.4%
H
0.7
8.0
|
L
 38.0%
H
0.7
8.0
|
L
 -73.5%
H
0.7
32.9
|
| Phio Pharma Corp |
|
11.8
|
1.0
|
L
 2%
H
1
1.0
|
L
H
1.0
1.1
|
L
 -13.6%
H
1.0
1.2
|
L
 -2.9%
H
0.8
1.2
|
L
 -54.5%
H
0.8
4.2
|
L
 -91.8%
H
0.6
29.1
|
L
 -99.6%
H
0.6
261.4
|
L
 -100.0%
H
0.6
174042
|
| Pharvaris NV |
|
2,321.7
|
33.1
|
L
 -6.1%
H
32.9
35.3
|
L
 -13.1%
H
32.9
38.9
|
L
 -8.8%
H
32.9
43.3
|
L
 0.2%
H
31.5
43.3
|
L
 32.3%
H
20.7
43.3
|
L
 62.7%
H
11.5
43.3
|
L
 81.7%
H
1.8
43.3
|
L
H
1.8
43.3
|
| Pliant Therapeutics Inc |
|
69.4
|
1.1
|
L
 -1.8%
H
1.1
1.1
|
L
H
1.1
1.2
|
L
 -3.5%
H
1.1
1.2
|
L
 -3.5%
H
1.0
1.2
|
L
 -25.3%
H
1.0
2.0
|
L
 -92.5%
H
1.0
19.6
|
L
 -93.6%
H
1.0
36.6
|
L
H
1.0
43.9
|
| Pluri Inc |
|
13.1
|
1.1
|
L
 -3.6%
H
1.0
1.1
|
L
 -9.4%
H
1
1.3
|
L
 -38.0%
H
1
1.7
|
L
 -47.5%
H
1
2.4
|
L
 -77.5%
H
1
4.9
|
L
 -77.2%
H
0.7
8.5
|
L
 -95.5%
H
0.7
25.5
|
L
 -99.2%
H
0.7
169.6
|
| ProMIS Neurosciences Inc |
|
116.0
|
12.9
|
L
 -4.7%
H
12.9
13.8
|
L
 0.4%
H
12.4
14.2
|
L
 -10.8%
H
12.3
15.5
|
L
 21.2%
H
10.2
17.3
|
L
 20.7%
H
6.3
27.4
|
L
 -74.2%
H
6.3
77.5
|
L
 -94.2%
H
6.3
245
|
L
 -91.4%
H
6.3
1050
|
| PMV Pharmaceuticals Inc |
|
73.2
|
1.4
|
L
 -9.3%
H
1.4
1.5
|
L
 0.7%
H
1.4
1.5
|
L
 3.0%
H
1.1
1.5
|
L
 20.2%
H
1.0
1.5
|
L
 2.2%
H
1.0
1.9
|
L
 -78.5%
H
0.8
6.7
|
L
 -95.2%
H
0.8
30.5
|
L
H
0.8
63.2
|
| Prelude Therapeutics Inc |
|
344.0
|
4.3
|
L
 -11.1%
H
4.2
4.9
|
L
 -4.7%
H
4.2
4.9
|
L
 -35.0%
H
4.2
6.8
|
L
 -0.2%
H
3.8
6.8
|
L
 326.7%
H
1.0
6.8
|
L
 53.4%
H
0.6
6.8
|
L
 -87.3%
H
0.6
37.0
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
567.7
|
3.1
|
L
 -11.6%
H
3.1
3.5
|
L
 -0.3%
H
2.9
3.6
|
L
 -7.7%
H
2.9
3.9
|
L
 -7.1%
H
2.7
4.8
|
L
 -37.3%
H
2.7
6.9
|
L
 -71.8%
H
1.1
11.1
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
344.7
|
1.7
|
L
 -9.8%
H
1.7
1.8
|
L
 -5.2%
H
1.7
2.0
|
L
 2.5%
H
1.6
2.1
|
L
 -9.3%
H
1.3
2.2
|
L
 -41.3%
H
1.3
3.5
|
L
 -65.8%
H
0.5
7.1
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
445.6
|
8.7
|
L
 -3.5%
H
8.7
9.0
|
L
 4.2%
H
8.2
9.1
|
L
 -8.2%
H
8.2
9.9
|
L
 -5.1%
H
8
10.2
|
L
 4.7%
H
7.7
11.8
|
L
 -83.0%
H
4.3
55.9
|
L
 -88.6%
H
4.3
79.8
|
L
 -86.4%
H
4.3
79.8
|
| Quince Therapeutics Inc |
|
30.7
|
30.2
|
L
 -3.8%
H
29.0
31.0
|
L
 4.5%
H
25.8
33.0
|
L
 -11.1%
H
25.8
35.3
|
L
 3141.9%
H
0.9
35.4
|
L
 86.1%
H
0.8
45.5
|
L
 162.2%
H
0.8
45.5
|
L
 -96.6%
H
0.8
985
|
L
H
0.8
1219.8
|
| uniQure NV |
|
2,966.1
|
42.8
|
L
 -5.6%
H
42.6
45.4
|
L
 -0.8%
H
41.7
45.8
|
L
 -11.6%
H
41.7
51.7
|
L
 -3.7%
H
35.3
51.7
|
L
 209.2%
H
8.7
71.5
|
L
 503.1%
H
3.7
71.5
|
L
 12.9%
H
3.7
71.5
|
L
 461.9%
H
3.7
82.5
|
| Rani Therapeutics Holdings Inc |
|
88.9
|
0.8
|
L
 -1.3%
H
0.8
0.8
|
L
 -6.1%
H
0.8
0.9
|
L
 -12.5%
H
0.8
0.9
|
L
H
0.6
0.9
|
L
 54%
H
0.4
3.9
|
L
 -72.3%
H
0.4
8.8
|
L
 -95.6%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
331.5
|
3.0
|
L
 -9.9%
H
3.0
3.3
|
L
 -11.4%
H
3.0
3.8
|
L
 -14.0%
H
3.0
4.0
|
L
 -12.7%
H
3.0
4.3
|
L
 -5.0%
H
2.5
5.5
|
L
 -85.2%
H
2.2
32.5
|
L
 -90.7%
H
2.2
36.9
|
L
 -91.5%
H
2.2
67.5
|
| Replimune Grp Inc |
|
1,221.1
|
13.0
|
L
 -3.8%
H
12.7
13.6
|
L
 -0.5%
H
12.6
13.6
|
L
 -12.3%
H
12.4
16.3
|
L
 15.9%
H
4.8
16.3
|
L
 296.3%
H
1.5
16.3
|
L
 -22.8%
H
1.5
17.1
|
L
 -60.8%
H
1.5
35.9
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
3.7
|
0.9
|
L
 -5.1%
H
0.9
1.0
|
L
 2.2%
H
0.9
1.0
|
L
 -14.7%
H
0.9
1.1
|
L
 -11.4%
H
0.9
1.2
|
L
 -84.7%
H
0.9
6.8
|
L
 -100.0%
H
0.9
4849.9
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Relay Therapeutics Inc |
|
3,951.1
|
18.0
|
L
 -6.8%
H
17.2
19.2
|
L
 -5.0%
H
17.2
19.7
|
L
 -7.3%
H
17.2
20.8
|
L
 4.3%
H
16.6
21.3
|
L
 297.1%
H
4.3
21.3
|
L
 109.2%
H
1.8
21.3
|
L
 -51.5%
H
1.8
38.2
|
L
H
1.8
64.4
|
| Rallybio Corp |
|
89.6
|
16.9
|
L
 -0.4%
H
16.6
16.9
|
L
 -2.1%
H
16.6
17.2
|
L
 0.2%
H
16.5
17.3
|
L
 5.8%
H
15.6
17.4
|
L
 246.2%
H
3.7
17.6
|
L
 -56.6%
H
1.8
40.2
|
L
 -82.9%
H
1.8
168
|
L
H
1.8
206.2
|
| TransCode Therapeutics Inc |
|
28.4
|
1.7
|
L
 -5.1%
H
1.6
2.4
|
L
 5%
H
1.6
2.4
|
L
 -41.5%
H
1.6
2.9
|
L
 -66.4%
H
1.6
10.7
|
L
 -85.2%
H
1.6
21.0
|
L
 -100.0%
H
1.6
118272
|
L
 -100.0%
H
1.6
3901941.1
|
L
H
1.6
5174400
|
| Recursion Pharma Inc (Class A) |
|
1,984.2
|
3.7
|
L
 -8.6%
H
3.7
4.1
|
L
 14.2%
H
3.2
4.2
|
L
 5.7%
H
3.1
4.2
|
L
 16.4%
H
2.8
4.2
|
L
 -25.7%
H
2.8
7.2
|
L
 -53.3%
H
2.8
15.7
|
L
 -84.8%
H
2.8
26
|
L
H
2.8
42.8
|
| SAB Biotherapeutics Inc |
|
308.4
|
3.4
|
L
 -3.1%
H
3.3
3.6
|
L
 -0.6%
H
3.3
3.6
|
L
 -10.3%
H
3.3
4.0
|
L
 -13.7%
H
3.3
4.1
|
L
 36.7%
H
1.9
5.2
|
L
 516.4%
H
0.4
6.6
|
L
 -66.2%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
922.0
|
3.1
|
L
 -7.5%
H
3.0
3.3
|
L
 -2.5%
H
2.9
3.4
|
L
 -21.2%
H
2.9
4.2
|
L
 -8.3%
H
2.9
4.2
|
L
 -5.2%
H
2.6
6.6
|
L
 -19.6%
H
1.3
12
|
L
 -86.2%
H
1.3
23.5
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
42.0
|
0.9
|
L
 -15.5%
H
0.8
1
|
L
 24.3%
H
0.7
1.3
|
L
 -9.4%
H
0.7
1.3
|
L
 -29.8%
H
0.7
1.4
|
L
 -62.5%
H
0.7
5.0
|
L
 -95.0%
H
0.7
42.2
|
L
 -98.3%
H
0.7
100
|
L
 -95.7%
H
0.7
146.2
|
| Seer Inc (Class A) |
|
99.7
|
1.8
|
L
 -3.2%
H
1.8
1.9
|
L
 -5.3%
H
1.8
1.9
|
L
 -11.3%
H
1.8
2.1
|
L
 2.3%
H
1.6
2.3
|
L
 -18.6%
H
1.6
2.4
|
L
 -21.4%
H
1.5
2.6
|
L
 -95.1%
H
1.5
38.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,218.7
|
7.9
|
L
 -2.6%
H
7.7
8.2
|
L
 -0.3%
H
7.7
8.3
|
L
 -21.6%
H
7.7
10.9
|
L
 -20.9%
H
7.3
11
|
L
 -21.6%
H
5.6
11
|
L
 -23.3%
H
5.6
15.6
|
L
 -23.3%
H
5.6
15.6
|
L
 -23.3%
H
5.6
15.6
|
| Solid Biosciences Inc |
|
859.9
|
8.0
|
L
 -10.1%
H
8
8.9
|
L
 -4.2%
H
8
9.0
|
L
 -13.8%
H
8
10.5
|
L
 -3.4%
H
7.7
11.5
|
L
 55.1%
H
3.8
11.5
|
L
 190.6%
H
1.8
15.1
|
L
 -82.2%
H
1.8
50.4
|
L
H
1.8
822.6
|
| Decoy Therapeutics Inc |
|
2.5
|
3.9
|
L
 24.2%
H
3.8
4.7
|
L
 42.1%
H
2.2
7.6
|
L
 20.3%
H
2.2
7.6
|
L
 -38.9%
H
2.2
13.5
|
L
 -92.4%
H
2.2
55.9
|
L
 -99.6%
H
2.2
1368
|
L
 -100.0%
H
2.2
43200
|
L
 -100.0%
H
2.2
10791000
|
| Summit Therapeutics Inc |
|
13,123.0
|
16.5
|
L
 -3.9%
H
16.3
17.5
|
L
 -5.5%
H
16.3
18.4
|
L
 25%
H
12.2
18.8
|
L
 15.2%
H
12.1
18.8
|
L
 -13.9%
H
12.1
29.2
|
L
 779.7%
H
1.6
36.9
|
L
 217.6%
H
0.7
36.9
|
L
 91.3%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,575.2
|
17.6
|
L
 -3.0%
H
17.1
18.5
|
L
 -2.5%
H
17.1
18.6
|
L
 -10.2%
H
17.1
21
|
L
 -8.7%
H
17.1
25.2
|
L
 18.5%
H
13.0
25.6
|
L
 10.5%
H
8.6
25.6
|
L
 -6.3%
H
8.6
29.9
|
L
 29.2%
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
815.3
|
31.6
|
L
 -5.5%
H
31.3
34.0
|
L
 -10.8%
H
31.3
37.4
|
L
 -1.4%
H
30.3
42.1
|
L
 36.1%
H
21.1
42.1
|
L
 252.5%
H
7.5
42.1
|
L
 81.3%
H
5
42.1
|
L
 -86.4%
H
5
238.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
10.6
|
0.3
|
L
 6.3%
H
0.3
0.4
|
L
 13.3%
H
0.3
0.4
|
L
 -12.8%
H
0.3
0.4
|
L
 -65.3%
H
0.3
1.2
|
L
 -75.5%
H
0.3
2.9
|
L
 -92.4%
H
0.3
16.9
|
L
 -65.7%
H
0.3
87.7
|
L
H
0.3
87.7
|
| Spruce Biosciences Inc |
|
142.0
|
49.4
|
L
 -1.1%
H
45.0
50.7
|
L
 -10.4%
H
45.0
57.1
|
L
 -4.2%
H
45.0
64.5
|
L
 -9.7%
H
40.3
64.5
|
L
 444.3%
H
7.3
240
|
L
 -72.3%
H
4.3
446.3
|
L
 -89.6%
H
4.3
486
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
73.4
|
1.3
|
L
 -7.4%
H
1.2
1.4
|
L
 11.5%
H
1.1
1.4
|
L
 3.3%
H
1.1
1.4
|
L
 -43.0%
H
1.1
2.3
|
L
 -37.9%
H
1.1
3.1
|
L
 4.1%
H
0.5
3.2
|
L
 -93.5%
H
0.5
19.9
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
6,071.0
|
49.9
|
L
 -2.6%
H
49.3
51.7
|
L
 -0.3%
H
45.9
51.7
|
L
 -11.8%
H
45.9
61.8
|
L
 1.3%
H
45.7
61.8
|
L
 53.0%
H
27.1
61.8
|
L
 683.8%
H
6.2
61.8
|
L
 60.5%
H
4.3
61.8
|
L
H
4.3
70
|
| Surrozen Inc |
|
189.9
|
16.2
|
L
 -8.2%
H
16.1
17.5
|
L
 -9.1%
H
16.1
17.9
|
L
 -32.6%
H
16.1
25.0
|
L
 -31.7%
H
16.1
27.3
|
L
 32.5%
H
11.4
35
|
L
 3491.1%
H
0.3
35
|
L
 49.6%
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,684.8
|
26.1
|
L
 -10.6%
H
26.0
29.2
|
L
 -7.3%
H
26.0
29.4
|
L
 -19.1%
H
26.0
33.9
|
L
 -15.7%
H
26.0
33.9
|
L
 14.3%
H
20.3
40.2
|
L
 524.6%
H
3.4
40.2
|
L
 -3.4%
H
3.4
40.2
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
638.3
|
6.4
|
L
 -2.2%
H
6.3
6.6
|
L
 6.5%
H
5.8
6.6
|
L
 -15.5%
H
5.8
8.2
|
L
 21.4%
H
5.1
8.2
|
L
 159.6%
H
1.7
8.3
|
L
 321.2%
H
0.7
11.8
|
L
 -66.4%
H
0.7
21.4
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
4.1
|
1.2
|
L
 11.5%
H
1.0
1.2
|
L
 36.5%
H
0.9
1.2
|
L
 2.7%
H
0.8
1.2
|
L
 -31.4%
H
0.8
1.9
|
L
 -79.0%
H
0.8
8.6
|
L
 -99.3%
H
0.8
367.2
|
L
H
0.8
2076
|
L
H
0.8
2076
|
| Alaunos Therapeutics Inc |
|
2.9
|
1.2
|
L
 -9.5%
H
1.1
1.3
|
L
 -18.4%
H
1.0
1.7
|
L
 -34.7%
H
1.0
1.8
|
L
 -46.8%
H
1.0
2.5
|
L
 -53.6%
H
1.0
4.6
|
L
 784.6%
H
0.0
6.2
|
L
 -39.2%
H
0.0
6.2
|
L
 -80.3%
H
0.0
7.9
|
| Tscan Therapeutics Inc |
|
24.4
|
0.4
|
L
H
0.3
0.4
|
L
 12.5%
H
0.3
0.4
|
L
 -53.9%
H
0.3
0.8
|
L
 -58.1%
H
0.3
1.3
|
L
 -79.8%
H
0.3
2.6
|
L
 -86.4%
H
0.3
9.7
|
L
 -94.2%
H
0.3
9.7
|
L
H
0.3
14.7
|
| Bio-Techne |
|
11,372.5
|
72.5
|
L
 0.0%
H
72.5
72.6
|
L
 0.3%
H
72.2
72.7
|
L
 0.4%
H
72.1
72.7
|
L
 30.4%
H
55.8
72.7
|
L
 36.7%
H
43.2
72.7
|
L
 4.6%
H
43.2
85.6
|
L
 -45.6%
H
43.2
136.0
|
L
 164.9%
H
23.9
136.0
|
| Instil Bio Inc |
|
49.1
|
7.2
|
L
 1.5%
H
7.0
7.4
|
L
 0.4%
H
6.9
7.4
|
L
 -4.5%
H
6.9
7.9
|
L
 -4.2%
H
6.9
8.1
|
L
 -62.6%
H
5.7
22.0
|
L
 1623.8%
H
0.3
92
|
L
 -66.3%
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
4,122.5
|
24.5
|
L
 -4.2%
H
24.1
25.9
|
L
 2.3%
H
21.6
25.9
|
L
 2.4%
H
21.6
27
|
L
 -14.2%
H
21.6
33.5
|
L
 228.2%
H
6.7
34.4
|
L
 136.9%
H
1.0
34.4
|
L
 54.7%
H
1.0
34.4
|
L
H
1.0
34.4
|
| Entrada Therapeutics Inc |
|
253.1
|
6.5
|
L
 -3.1%
H
6.4
6.7
|
L
 -5.5%
H
6.4
7.1
|
L
 -14.1%
H
6.3
7.7
|
L
 -8.1%
H
5.7
8.1
|
L
 23.1%
H
5.1
16.5
|
L
 -54.9%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
2,060.2
|
14.5
|
L
 -5.1%
H
14.4
15.2
|
L
 -3.9%
H
14.4
15.6
|
L
 -19.5%
H
14.4
18.6
|
L
 -18.4%
H
14.4
20.2
|
L
 69.1%
H
8.2
20.2
|
L
 582.1%
H
1.0
20.2
|
L
 1003.8%
H
0.5
20.2
|
L
H
0.5
20.2
|
| Taysha Gene Therapies Inc |
|
1,599.8
|
4.9
|
L
 -4.8%
H
4.9
5.1
|
L
 -3.0%
H
4.9
5.5
|
L
 -19.4%
H
4.9
6.3
|
L
 -24.8%
H
4.9
7.1
|
L
 71.1%
H
2.9
7.3
|
L
 67.6%
H
1.1
7.3
|
L
 -74.1%
H
0.5
20.5
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
10,508.7
|
158.5
|
L
 -3.7%
H
157.4
166.4
|
L
 14.8%
H
137.1
170.7
|
L
 8.9%
H
120.2
170.7
|
L
 86.1%
H
80.6
170.7
|
L
 469.9%
H
23.3
170.7
|
L
 679.3%
H
14.4
170.7
|
L
 31.1%
H
11.5
170.7
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
9,852.6
|
75.6
|
L
 -6.3%
H
74.8
81.9
|
L
 1.7%
H
71.4
82.7
|
L
 16.1%
H
58.7
82.7
|
L
 129.6%
H
31.3
82.7
|
L
 479.9%
H
11.2
82.7
|
L
 82.9%
H
6.8
82.7
|
L
 -52.4%
H
6.8
187.9
|
L
H
6.8
209.0
|
| Tyra Biosciences Inc |
|
1,597.2
|
23.2
|
L
 -9.2%
H
22.9
25.4
|
L
 -8.7%
H
22.9
27.0
|
L
 -10.8%
H
18.7
29.6
|
L
 -22.9%
H
18.7
33.7
|
L
 80.2%
H
12.4
40.7
|
L
 63.1%
H
6.4
40.7
|
L
 26.2%
H
4.9
40.7
|
L
H
4.9
40.7
|
| Unicycive Therapeutics Inc |
|
134.0
|
4.8
|
L
 -3.0%
H
4.7
5.0
|
L
 2.1%
H
4.7
5.0
|
L
 -14.6%
H
4.7
5.6
|
L
 -38.9%
H
3.9
8.6
|
L
 21.5%
H
3.7
8.7
|
L
 -26.2%
H
2.0
18.2
|
L
 -81.6%
H
2.0
31.3
|
L
H
2.0
87.3
|
| TradeUP Acq Corp |
|
-
|
0.5
|
L
 -2.1%
H
0.5
0.5
|
L
 -23.0%
H
0.5
0.7
|
L
 -36.5%
H
0.5
0.8
|
L
 -49.5%
H
0.5
1.1
|
L
 -59.5%
H
0.5
3.2
|
L
 -96.3%
H
0.5
15.5
|
L
 -95.2%
H
0.5
33
|
L
H
0.5
33
|
| UroGen Pharma Ltd |
|
2,034.9
|
41.6
|
L
 -2.6%
H
39.7
42.7
|
L
 -0.3%
H
39.7
45.3
|
L
 -11.2%
H
39.7
47.2
|
L
 19.0%
H
33.7
50.8
|
L
 131.4%
H
15.9
50.8
|
L
 165.3%
H
3.4
50.8
|
L
 145.2%
H
3.4
50.8
|
L
H
3.4
69.6
|
| United Therapeutics Corp |
|
20,991.6
|
489.4
|
L
 -1.6%
H
487.7
500.1
|
L
 -2.2%
H
487.7
505.8
|
L
 -4.6%
H
477.0
531.8
|
L
 -9.1%
H
477.0
563.7
|
L
 18.0%
H
409.1
609.4
|
L
 119.7%
H
208.6
609.4
|
L
 142.4%
H
158.4
609.4
|
L
 285.3%
H
74.3
609.4
|
| Vera Therapeutics Inc (Class A) |
|
2,381.7
|
33.1
|
L
 -8.9%
H
32.6
36.5
|
L
 -1.8%
H
31.2
36.5
|
L
 2.4%
H
31.2
37.1
|
L
 -14%
H
28.9
44.9
|
L
 26.6%
H
23.1
56.1
|
L
 127.6%
H
9.2
56.1
|
L
 107.6%
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,876.6
|
11.1
|
L
 -3.6%
H
10.9
11.5
|
L
 6.2%
H
10.4
11.7
|
L
 13.4%
H
9.4
11.9
|
L
 15.9%
H
8.5
11.9
|
L
 110.4%
H
4.8
11.9
|
L
 18.6%
H
4.2
14.5
|
L
 -75.9%
H
4.2
58
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
1,146.0
|
19.4
|
L
 -12.0%
H
18.9
22.0
|
L
 -13.2%
H
18.9
23.8
|
L
 -17.1%
H
18.9
26
|
L
 29.7%
H
14.2
26
|
L
 -30.7%
H
6.5
50.0
|
L
 796.8%
H
0.1
50.0
|
L
 36.2%
H
0.1
50.0
|
L
H
0.1
63.6
|
| Verastem Inc |
|
740.8
|
8.2
|
L
 -2.3%
H
7.9
8.4
|
L
 11.4%
H
7.2
8.6
|
L
 18.7%
H
6.6
8.6
|
L
 92.5%
H
3.4
8.6
|
L
 -10.4%
H
3.4
10.8
|
L
 -15.7%
H
2.1
14.2
|
L
 -77.2%
H
2.1
39.6
|
L
 -50.2%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
16.4
|
0.4
|
L
 48%
H
0.3
0.6
|
L
 54.2%
H
0.2
0.6
|
L
 54.2%
H
0.2
0.6
|
L
 -42.2%
H
0.2
0.8
|
L
 -88.9%
H
0.2
5.1
|
L
 -93.0%
H
0.2
5.9
|
L
 -99.6%
H
0.2
89.4
|
L
 -99.7%
H
0.2
140.7
|
| Voyager Therapeutics Inc |
|
176.8
|
2.9
|
L
 -8.6%
H
2.9
3.1
|
L
 -7.1%
H
2.9
3.2
|
L
 -15.3%
H
2.9
3.6
|
L
 -22.9%
H
2.9
3.9
|
L
 -32.0%
H
2.9
5.6
|
L
 -62.2%
H
2.6
11.7
|
L
 -1.7%
H
2.5
14.3
|
L
 -79.3%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
602.1
|
6.4
|
L
 -3.6%
H
6.3
6.5
|
L
 -3.1%
H
6.3
6.8
|
L
 -8.8%
H
6.3
7.2
|
L
 18.7%
H
4.8
7.3
|
L
 -37.4%
H
4.8
12.2
|
L
 -50.3%
H
3.6
14.5
|
L
 -79.8%
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
778.3
|
4.0
|
L
 -9.2%
H
3.9
4.4
|
L
 -11.4%
H
3.9
4.6
|
L
 -25.3%
H
3.9
5.3
|
L
 -36.0%
H
3.9
6.5
|
L
 -42.8%
H
3.9
21.7
|
L
 -27.4%
H
3.5
21.7
|
L
 -32.5%
H
1.2
21.7
|
L
 -88.2%
H
1.2
56
|
| XBiotech Inc |
|
66.5
|
2.2
|
L
H
2.2
2.2
|
L
 -0.9%
H
2.1
2.2
|
L
 -4.4%
H
2.1
2.3
|
L
 -5.6%
H
2.1
2.5
|
L
 -20.7%
H
2.1
3.4
|
L
 -50%
H
2.1
10.0
|
L
 -85.4%
H
2.1
16.5
|
L
 -83.7%
H
2.1
26.4
|
| Exicure Inc |
|
8.1
|
1.2
|
L
 -3.9%
H
1.2
1.3
|
L
 -5.3%
H
1.2
1.4
|
L
 7.8%
H
1.1
1.6
|
L
 -54.7%
H
1.1
3.0
|
L
 -66.7%
H
1.1
9.5
|
L
 -67.0%
H
0.3
36
|
L
 -99.4%
H
0.3
202.5
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
1,578.9
|
8.7
|
L
 -0.8%
H
8.5
9.2
|
L
 15.6%
H
7.5
9.2
|
L
 -0.5%
H
7.4
9.2
|
L
 25.5%
H
6.9
9.2
|
L
 10.2%
H
5.3
10.1
|
L
 381.1%
H
1.5
10.1
|
L
 259.3%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
308.3
|
3.1
|
L
 -9.3%
H
3.0
3.4
|
L
 -14.1%
H
3.0
3.7
|
L
 -23.0%
H
3.0
4.4
|
L
 -24.5%
H
3.0
4.8
|
L
 -8.0%
H
2.8
4.8
|
L
 199.0%
H
0.2
6.6
|
L
 -40.8%
H
0.2
6.6
|
L
H
0.2
172.2
|
| Xencor Inc |
|
1,803.8
|
24.3
|
L
 -3.6%
H
24.0
25.6
|
L
 2.2%
H
23.6
25.7
|
L
 -12.7%
H
23.4
30.6
|
L
 73.2%
H
13.9
30.6
|
L
 133.5%
H
10.2
30.6
|
L
 20.3%
H
6.9
30.6
|
L
 -27.4%
H
6.9
43.6
|
L
 -3.6%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
1.7
|
2.3
|
L
 29.3%
H
1.7
2.6
|
L
 30%
H
1.7
2.6
|
L
 -37.8%
H
1.7
4.1
|
L
 -47.9%
H
1.7
5.0
|
L
 -90.2%
H
0.3
32.3
|
L
 -100.0%
H
0.3
794926.0
|
L
 -100.0%
H
0.3
39346560
|
L
 -100.0%
H
0.3
67850460
|
| Zentalis Pharma Inc |
|
271.7
|
2.9
|
L
 -6.8%
H
2.8
3.1
|
L
 -8.3%
H
2.8
3.3
|
L
 -24.9%
H
2.8
4.2
|
L
 -21.8%
H
2.8
5.6
|
L
 88.8%
H
1.2
7.0
|
L
 -86.5%
H
1.0
21.3
|
L
 -95.5%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
414.9
|
4.3
|
L
 -4.0%
H
4.2
4.6
|
L
 -12.2%
H
4.2
5.0
|
L
 -26.0%
H
4.2
7.1
|
L
 2.4%
H
4.1
7.1
|
L
 105.2%
H
2.0
7.4
|
L
 -32.3%
H
1.0
7.4
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
2,968.3
|
26.4
|
L
 0.1%
H
26.3
26.8
|
L
 6.6%
H
24.4
27.1
|
L
 1.7%
H
23.6
27.5
|
L
 43.1%
H
17.2
27.5
|
L
 -20.2%
H
16.0
34.7
|
L
 8.1%
H
13.5
44.3
|
L
 -77.7%
H
13.5
123.3
|
L
H
13.5
193.5
|
| Intensity Therapeutics Inc |
|
13.4
|
4.1
|
L
 2.2%
H
4.0
4.1
|
L
 7.6%
H
3.8
4.3
|
L
 -15.6%
H
3.8
5.2
|
L
 4.1%
H
3.8
5.2
|
L
 -36.9%
H
3.5
43.5
|
L
 -95.9%
H
3.5
286
|
L
 -95.9%
H
3.5
286
|
L
 -95.9%
H
3.5
286
|
| Renovaro Biosciences Inc |
|
9.7
|
2.1
|
L
 -4.0%
H
2.1
2.4
|
L
 -2.3%
H
2.1
2.7
|
L
 -0.9%
H
2.1
2.9
|
L
 -48.4%
H
1.9
4.8
|
L
 -83.5%
H
1.2
14.4
|
L
 -99.3%
H
1.2
420
|
L
H
1.2
420
|
L
H
1.2
420
|
| Elutia Inc (Class A) |
|
38.5
|
0.9
|
L
 7.4%
H
0.9
0.9
|
L
 8.8%
H
0.8
0.9
|
L
 -8.4%
H
0.8
1.1
|
L
 -13%
H
0.8
1.1
|
L
 -21.6%
H
0.5
1.4
|
L
 -38.3%
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Dianthus Therapeutics Inc |
|
5,226.5
|
93.4
|
L
 -5.0%
H
89.8
98.5
|
L
 -10.8%
H
89.8
107
|
L
 -15.9%
H
89.8
113.9
|
L
 7.0%
H
84.6
117.9
|
L
 147.5%
H
32.2
117.9
|
L
 597.3%
H
6.6
117.9
|
L
 12194.7%
H
6.6
117.9
|
L
 12194.7%
H
6.6
117.9
|
| Incannex Healthcare Ltd (ADR) |
|
41.2
|
3.4
|
L
 1.2%
H
3.4
3.5
|
L
 -0.3%
H
3.4
3.8
|
L
 -3.6%
H
3.1
3.9
|
L
 5.9%
H
2.8
4.0
|
L
 -78.4%
H
2.5
20.3
|
L
 -97.9%
H
2.4
160.2
|
L
 -97.9%
H
2.4
160.2
|
L
 -97.9%
H
2.4
160.2
|
| Canton Strategic Holdings Inc |
|
178.5
|
2.2
|
L
 -8.6%
H
2.2
2.4
|
L
 9.8%
H
1.9
2.5
|
L
 2.3%
H
1.9
2.5
|
L
 -30.2%
H
1.8
3.3
|
L
 -23.0%
H
1.8
6.9
|
L
 -97.4%
H
0.3
142.5
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Estrella Biopharma Inc |
|
20.4
|
0.5
|
L
 -2.1%
H
0.5
0.5
|
L
 -23.0%
H
0.5
0.7
|
L
 -36.5%
H
0.5
0.8
|
L
 -49.5%
H
0.5
1.1
|
L
 -59.5%
H
0.5
3.2
|
L
 -96.3%
H
0.5
15.5
|
L
 -96.3%
H
0.5
15.5
|
L
 -96.3%
H
0.5
15.5
|
| Lexeo Therapeutics Inc |
|
289.0
|
3.5
|
L
 -13.5%
H
3.5
4.1
|
L
 -14.8%
H
3.5
4.4
|
L
 -27.9%
H
3.5
5.1
|
L
 -30.2%
H
3.5
5.4
|
L
 -33.7%
H
3.5
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Cartesian Therapeutics Inc |
|
238.1
|
7.9
|
L
 -2.6%
H
7.7
8.2
|
L
 -0.3%
H
7.7
8.3
|
L
 -21.6%
H
7.7
10.9
|
L
 -20.9%
H
7.3
11
|
L
 -21.6%
H
5.6
11
|
L
 -99.2%
H
5.6
1278
|
L
 -99.8%
H
5.6
4076.2
|
L
 -99.9%
H
5.6
25199.6
|
| Elevai Labs Inc |
|
3.7
|
4.5
|
L
 6.3%
H
4.3
4.6
|
L
 -6.0%
H
4.1
5.1
|
L
 -32.0%
H
4.1
6.9
|
L
 -66.4%
H
4.1
15.6
|
L
 -99.7%
H
4.1
2671.2
|
L
H
4.1
4991179.2
|
L
H
4.1
4991179.2
|
L
H
4.1
4991179.2
|
| Neurogene Inc |
|
619.0
|
30.9
|
L
 -8.0%
H
30.1
33.5
|
L
 -8.2%
H
30.1
35.6
|
L
 -19.9%
H
30.1
42.0
|
L
 -4.1%
H
29.7
43.7
|
L
 82.2%
H
15.9
43.7
|
L
 118.1%
H
6.9
74.5
|
L
 118.1%
H
6.9
74.5
|
L
 118.1%
H
6.9
74.5
|
| Cg Oncology Inc |
|
6,502.7
|
73.4
|
L
 -5.6%
H
71.9
77.8
|
L
 1.1%
H
71.9
80.6
|
L
 -8.1%
H
70
80.6
|
L
 10.7%
H
63.8
81.0
|
L
 98.1%
H
35.6
81.0
|
L
H
14.8
81.0
|
L
H
14.8
81.0
|
L
H
14.8
81.0
|
| FibroBiologics Inc |
|
9.3
|
1.3
|
L
 -0.8%
H
1.3
1.5
|
L
 -7.6%
H
1.3
1.6
|
L
 -7.6%
H
1.3
2.2
|
L
 64.2%
H
0.6
2.2
|
L
 -87.4%
H
0.6
12.4
|
L
H
0.6
1100
|
L
H
0.6
1100
|
L
H
0.6
1100
|
| Alto Neuroscience Inc |
|
1,079.2
|
27.5
|
L
 -10.7%
H
26.4
30.6
|
L
 -9.1%
H
26.4
31.7
|
L
 -19.8%
H
26.4
37.5
|
L
 19.9%
H
22.3
37.5
|
L
 591.0%
H
3.8
37.5
|
L
H
1.6
37.5
|
L
H
1.6
37.5
|
L
H
1.6
37.5
|
| Fractyl Health Inc |
|
78.0
|
0.5
|
L
 -10.9%
H
0.5
0.6
|
L
 -12.5%
H
0.5
0.6
|
L
 -37.2%
H
0.5
0.8
|
L
 -43.7%
H
0.5
1.0
|
L
 -50.5%
H
0.4
2.4
|
L
H
0.4
15
|
L
H
0.4
15
|
L
H
0.4
15
|
| Kyverna Therapeutics Inc |
|
437.2
|
7.1
|
L
 -5.9%
H
7.0
7.5
|
L
 1.6%
H
6.9
7.6
|
L
 -16.0%
H
6.9
8.9
|
L
 -14.8%
H
6.9
10.3
|
L
 8.4%
H
5.3
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
42.7
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 -2.6%
H
1.1
1.2
|
L
 -8.1%
H
1.1
1.3
|
L
 -5.0%
H
1.1
1.4
|
L
 -51.7%
H
1.1
4.0
|
L
H
1.1
15
|
L
H
1.1
15
|
L
H
1.1
15
|
| NeOnc Tech Holdings Inc |
|
92.8
|
3.2
|
L
 -6.7%
H
3.1
3.5
|
L
 -2.7%
H
3.0
3.7
|
L
 -31.2%
H
3.0
5.2
|
L
 -37.0%
H
3.0
5.8
|
L
 -73.0%
H
3.0
13.0
|
L
H
3.0
13.0
|
L
H
3.0
13.0
|
L
H
3.0
13.0
|
| LENZ Therapeutics Inc |
|
118.1
|
3.8
|
L
 -9.0%
H
3.7
4.1
|
L
 -11.1%
H
3.7
4.3
|
L
 -19.7%
H
3.7
6.0
|
L
 -35.4%
H
3.7
6.7
|
L
 -90.9%
H
3.7
50.4
|
L
 -84.9%
H
3.7
50.4
|
L
 -84.9%
H
3.7
50.4
|
L
 -84.9%
H
3.7
50.4
|
| Boundless Bio Inc |
|
61.4
|
2.7
|
L
 -6.3%
H
2.7
2.9
|
L
 -3.9%
H
2.7
2.9
|
L
 -10%
H
2.7
3.2
|
L
 92.9%
H
2.3
3.2
|
L
 138.9%
H
1.0
3.2
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
470.6
|
12.5
|
L
 -6.6%
H
12.4
13.3
|
L
 -9.5%
H
12.4
14.6
|
L
 -27.2%
H
12.4
17.8
|
L
 7.7%
H
11.4
17.8
|
L
 11%
H
8.6
17.8
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
537.8
|
8.1
|
L
 -5.1%
H
8.0
8.6
|
L
 0.4%
H
8.0
8.8
|
L
 21.0%
H
6.3
8.8
|
L
 22.6%
H
5.7
8.8
|
L
 22.4%
H
5.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
27.5
|
3.9
|
L
 -0.8%
H
3.8
4.1
|
L
 27.8%
H
2.9
4.1
|
L
 8.1%
H
2.7
4.2
|
L
 -20.6%
H
2.6
5.1
|
L
 -22.7%
H
1.9
6.9
|
L
 -53.7%
H
0.6
9.5
|
L
 -53.7%
H
0.6
9.5
|
L
 -53.7%
H
0.6
9.5
|
| Inhibrx Biosciences Inc |
|
1,476.6
|
100.3
|
L
 -9.3%
H
98.6
110.9
|
L
 -5%
H
98.6
117.1
|
L
 -3.2%
H
94
131.0
|
L
 7.5%
H
77.5
131.0
|
L
 270.0%
H
27.1
155.3
|
L
 713.7%
H
12.2
155.3
|
L
 713.7%
H
12.2
155.3
|
L
 713.7%
H
12.2
155.3
|
| Rapport Therapeutics Inc |
|
1,637.5
|
34.1
|
L
 -17.7%
H
33.4
41.5
|
L
 -20.0%
H
33.4
43.7
|
L
 -29.3%
H
33.4
52.9
|
L
 -10.6%
H
33.4
52.9
|
L
 30.7%
H
23.8
52.9
|
L
H
6.4
52.9
|
L
H
6.4
52.9
|
L
H
6.4
52.9
|
| Artiva Biotherapeutics Inc |
|
377.4
|
7.7
|
L
 -4.6%
H
7.5
8.2
|
L
 -13.4%
H
7.5
9.0
|
L
 -29.4%
H
7.5
12.1
|
L
 -17.5%
H
7.5
12.3
|
L
 185.9%
H
2.5
14.5
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
2,788.0
|
57.9
|
L
 -6.6%
H
57.8
61.9
|
L
 -5.2%
H
57.8
65
|
L
 -12.7%
H
57.8
69.5
|
L
 31.8%
H
42.0
72.6
|
L
 189.5%
H
12.9
72.6
|
L
H
4.8
72.6
|
L
H
4.8
72.6
|
L
H
4.8
72.6
|
| BioAge Labs Inc |
|
362.1
|
7.9
|
L
 -6.7%
H
7.7
8.5
|
L
 -3.6%
H
7.6
8.5
|
L
 -16.8%
H
7.6
10.3
|
L
 -63.3%
H
7.6
26.0
|
L
 54.4%
H
4.9
26.0
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| Voyager Acq Corp (Class A) |
|
44.0
|
1.4
|
L
 -1.4%
H
1.4
1.4
|
L
 -8.6%
H
1.4
1.6
|
L
 -28.7%
H
1.3
2
|
L
 -66.4%
H
1.3
3.9
|
L
 -86.7%
H
1.3
27.4
|
L
H
1.3
27.4
|
L
H
1.3
27.4
|
L
H
1.3
27.4
|
| OnKure Therapeutics Inc (Class A) |
|
119.1
|
2.9
|
L
 -5.2%
H
2.9
3.2
|
L
 0.3%
H
2.8
3.2
|
L
 -25.4%
H
2.8
4.4
|
L
 -33.8%
H
2.8
4.8
|
L
 12.6%
H
2.2
5.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
3.7
|
L
 -10.4%
H
3.7
4.3
|
L
 -11.2%
H
3.7
4.4
|
L
 -17.0%
H
3.7
4.6
|
L
 -11.4%
H
2.9
6
|
L
 35.3%
H
2.5
7.8
|
L
 61.7%
H
1.3
7.8
|
L
 61.7%
H
1.3
7.8
|
L
 61.7%
H
1.3
7.8
|
| Upstream Bio Inc |
|
284.3
|
5.2
|
L
 -5.5%
H
5.0
5.5
|
L
 -5.3%
H
5.0
5.6
|
L
 -25.5%
H
5.0
7.3
|
L
 -17.6%
H
5.0
8
|
L
 -68.8%
H
5.0
33.7
|
L
H
5.0
33.7
|
L
H
5.0
33.7
|
L
H
5.0
33.7
|
| Septerna Inc |
|
1,794.7
|
38.5
|
L
 -4.8%
H
37.0
40.2
|
L
 -1.1%
H
37.0
41.1
|
L
 -3.9%
H
36.0
41.9
|
L
 10.3%
H
30.6
51.1
|
L
 140.3%
H
15.9
51.1
|
L
H
4.2
51.1
|
L
H
4.2
51.1
|
L
H
4.2
51.1
|
| Polyrizon Ltd |
|
26.8
|
11.2
|
L
 4.7%
H
10.1
12.0
|
L
 -2.0%
H
9.2
12.0
|
L
 8.4%
H
9.2
15.3
|
L
 -15.4%
H
9.1
16.5
|
L
 64.6%
H
2.9
18.2
|
L
H
2.9
7200
|
L
H
2.9
7200
|
L
H
2.9
7200
|
| Medicus Pharma Ltd |
|
11.5
|
0.2
|
L
H
0.2
0.2
|
L
 6.7%
H
0.2
0.2
|
L
 -40.7%
H
0.1
0.3
|
L
 -64.4%
H
0.1
0.5
|
L
 -94.1%
H
0.1
3.1
|
L
 -97.6%
H
0.1
8.9
|
L
 -97.6%
H
0.1
8.9
|
L
 -97.6%
H
0.1
8.9
|
| Telix Pharma Ltd (ADR) |
|
3,829.4
|
11.3
|
L
 -5.7%
H
11.2
11.5
|
L
 -12.2%
H
10.8
12.8
|
L
 -0.5%
H
10.8
13.1
|
L
 12.7%
H
9.8
13.1
|
L
 12.1%
H
6.3
13.1
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
| Palvella Therapeutics Inc |
|
2,154.9
|
149.6
|
L
 -5.4%
H
147.4
157.6
|
L
 -1.1%
H
147.4
160.8
|
L
 5.3%
H
136.1
160.8
|
L
 25.9%
H
116.8
161.4
|
L
 154.7%
H
56.5
161.4
|
L
 999.7%
H
11.2
161.4
|
L
 999.7%
H
11.2
161.4
|
L
 999.7%
H
11.2
161.4
|
| Zhengye biotech Holding Ltd |
|
64.9
|
1.4
|
L
 7.0%
H
1.3
1.4
|
L
 -0.7%
H
1.3
1.4
|
L
 -32.8%
H
1.3
2.1
|
L
 90.3%
H
0.6
8.0
|
L
 -84.3%
H
0.6
9.3
|
L
H
0.6
14.3
|
L
H
0.6
14.3
|
L
H
0.6
14.3
|
| Sionna Therapeutics Inc |
|
249.1
|
5.5
|
L
 -8.5%
H
5.3
6.1
|
L
 -19.9%
H
5.3
7.7
|
L
 4.2%
H
5.2
8.5
|
L
 -85.8%
H
4.0
55.0
|
L
 -78.7%
H
4.0
55.0
|
L
H
4.0
55.0
|
L
H
4.0
55.0
|
L
H
4.0
55.0
|
| Zenas Biopharma Inc |
|
1,931.2
|
29.6
|
L
 -10.4%
H
29.5
33.1
|
L
 -7.2%
H
29.5
33.8
|
L
 -8.2%
H
29.5
34.0
|
L
 42.5%
H
20.1
34.1
|
L
 56.4%
H
13.5
44.6
|
L
 183.0%
H
8.9
44.6
|
L
 183.0%
H
8.9
44.6
|
L
 183.0%
H
8.9
44.6
|
| Advanced Biomed Inc |
|
10.4
|
6.3
|
L
 -0.9%
H
6.3
6.7
|
L
 -21.8%
H
6.3
8.1
|
L
 -22.4%
H
6.3
10.8
|
L
 22.2%
H
4.1
24.2
|
L
 -30.6%
H
3.6
24.2
|
L
H
3.6
82
|
L
H
3.6
82
|
L
H
3.6
82
|
| Caris Life Sciences Inc (Class A) |
|
8,944.1
|
31.7
|
L
 0.6%
H
31.1
32.9
|
L
 11.1%
H
27.9
32.9
|
L
 20.5%
H
23.2
32.9
|
L
 82.8%
H
15.1
32.9
|
L
 -3.9%
H
14.2
33.7
|
L
 13.0%
H
14.2
42.5
|
L
 13.0%
H
14.2
42.5
|
L
 13.0%
H
14.2
42.5
|
| Propanc Biopharma Inc |
|
1.4
|
0.6
|
L
 -3.1%
H
0.6
0.7
|
L
 -23.2%
H
0.6
0.9
|
L
 -41.7%
H
0.6
4.1
|
L
 -57.4%
H
0.6
4.1
|
L
 -98.8%
H
0.6
52.5
|
L
 -99.1%
H
0.6
234
|
L
 -99.1%
H
0.6
234
|
L
 -99.1%
H
0.6
234
|
| SpyGlass Pharma Inc |
|
941.9
|
28.2
|
L
 -1.9%
H
27.8
29.3
|
L
 -2.8%
H
27.1
30.0
|
L
 6.2%
H
25.3
30.1
|
L
 45.6%
H
18.6
30.1
|
L
 6.7%
H
17.1
30.6
|
L
 6.7%
H
17.1
30.6
|
L
 6.7%
H
17.1
30.6
|
L
 6.7%
H
17.1
30.6
|
| AgomAb Therapeutics NV ADR |
|
529.9
|
10.8
|
L
 -6.4%
H
10.6
11.8
|
L
 -11.5%
H
10.6
13.0
|
L
 -18.8%
H
10.6
16.5
|
L
 -9.1%
H
10.6
17.8
|
L
 -26.6%
H
8.8
17.8
|
L
 -26.6%
H
8.8
17.8
|
L
 -26.6%
H
8.8
17.8
|
L
 -26.6%
H
8.8
17.8
|
| Generate Biomedicines Inc |
|
2,120.4
|
16.5
|
L
 -5.4%
H
16.5
17.6
|
L
 2.0%
H
15.6
18.0
|
L
 2.5%
H
14.7
22.7
|
L
 4.0%
H
12.5
22.7
|
L
 30.6%
H
11
22.7
|
L
 30.6%
H
11
22.7
|
L
 30.6%
H
11
22.7
|
L
 30.6%
H
11
22.7
|
| Atrium Therapeutics Inc |
|
142.5
|
8.3
|
L
 -9.7%
H
8.3
9.3
|
L
 -17.4%
H
8.3
10.1
|
L
 -36.9%
H
8.3
14.7
|
L
 -35.6%
H
8.3
14.7
|
L
 -43.5%
H
8.3
16.8
|
L
 -43.5%
H
8.3
16.8
|
L
 -43.5%
H
8.3
16.8
|
L
 -43.5%
H
8.3
16.8
|
| Jatt II Acquisition Corp |
|
88.5
|
11.3
|
L
 -3.1%
H
11
11.8
|
L
 -5.5%
H
11
12.9
|
L
 -14.4%
H
11
13.5
|
L
 5.5%
H
10.3
23.8
|
L
 8%
H
10
23.8
|
L
 8%
H
10
23.8
|
L
 8%
H
10
23.8
|
L
 8%
H
10
23.8
|
| Kailera Therapeutics Inc |
|
1,702.2
|
13.1
|
L
 2.7%
H
12.6
13.2
|
L
 -2.4%
H
11.8
13.7
|
L
 -23.5%
H
11.8
18.8
|
L
 -42.6%
H
11.8
23.8
|
L
 -49.5%
H
11.8
28.2
|
L
 -49.5%
H
11.8
28.2
|
L
 -49.5%
H
11.8
28.2
|
L
 -49.5%
H
11.8
28.2
|
| Alamar Biosciences Inc |
|
2,230.3
|
32.1
|
L
 -3.3%
H
32.1
33.7
|
L
 11.8%
H
28.5
37.8
|
L
 -6.1%
H
27.3
37.8
|
L
 41.1%
H
21.8
38.5
|
L
 46.1%
H
18.8
38.5
|
L
 46.1%
H
18.8
38.5
|
L
 46.1%
H
18.8
38.5
|
L
 46.1%
H
18.8
38.5
|
| LakewoodAmedex |
|
4.2
|
1.8
|
L
 -10.6%
H
1.8
2
|
L
 -18.0%
H
1.8
2.2
|
L
 -20.5%
H
1.8
2.9
|
L
 -51.2%
H
1.7
6.9
|
L
 -97.9%
H
1.7
94
|
L
 -97.9%
H
1.7
94
|
L
 -97.9%
H
1.7
94
|
L
 -97.9%
H
1.7
94
|
| Hemab Therapeutics Holdings |
|
1,715.7
|
36.7
|
L
 -4.0%
H
35.0
39.0
|
L
 -8.4%
H
35.0
44.0
|
L
 -25.3%
H
35.0
52
|
L
 15.7%
H
27.5
55.4
|
L
 8.0%
H
23
55.4
|
L
 8.0%
H
23
55.4
|
L
 8.0%
H
23
55.4
|
L
 8.0%
H
23
55.4
|
| Odyssey Therapeutics Inc |
|
997.7
|
20.8
|
L
 -11.1%
H
20.5
23.0
|
L
 -5.6%
H
20.5
25.8
|
L
 -21.3%
H
20.5
29.1
|
L
 10.9%
H
15.1
29.1
|
L
 26.4%
H
15.1
29.1
|
L
 26.4%
H
15.1
29.1
|
L
 26.4%
H
15.1
29.1
|
L
 26.4%
H
15.1
29.1
|
| Lakefront Biotherapeutics NV |
|
2,011.7
|
30.7
|
L
 1.8%
H
30.7
32.4
|
L
 10.0%
H
27.2
32.4
|
L
 6.7%
H
26.6
32.4
|
L
 6.2%
H
25.7
32.4
|
L
 7.5%
H
25.7
32.4
|
L
 7.5%
H
25.7
32.4
|
L
 7.5%
H
25.7
32.4
|
L
 7.5%
H
25.7
32.4
|
| Conexeu Sciences Inc |
|
118.8
|
4.2
|
L
 -4.3%
H
3.9
4.5
|
L
 -5.4%
H
3.9
5.5
|
L
 -52.6%
H
3.9
9.2
|
L
 -65.4%
H
3.9
13.7
|
L
 -67.8%
H
3.9
18.8
|
L
 -67.8%
H
3.9
18.8
|
L
 -67.8%
H
3.9
18.8
|
L
 -67.8%
H
3.9
18.8
|
| Veraxa Biotech AG |
|
196.6
|
1.4
|
L
 -1.4%
H
1.4
1.4
|
L
 -8.6%
H
1.4
1.6
|
L
 -28.7%
H
1.3
2
|
L
 -66.4%
H
1.3
3.9
|
L
 -94.4%
H
1.3
26.0
|
L
 -94.4%
H
1.3
26.0
|
L
 -94.4%
H
1.3
26.0
|
L
 -94.4%
H
1.3
26.0
|
| Kardigan Inc |
|
1,357.7
|
14.5
|
L
 -11.7%
H
14.2
16.5
|
L
 -21.8%
H
14.2
19.0
|
L
 -30.9%
H
14.2
22.5
|
L
 -36.2%
H
14.2
27
|
L
 -34%
H
14.2
27
|
L
 -34%
H
14.2
27
|
L
 -34%
H
14.2
27
|
L
 -34%
H
14.2
27
|
| Braveheart Bio Inc |
|
1,932.2
|
21.5
|
L
 -9.1%
H
21.3
23.8
|
L
 -19.7%
H
21.3
29.5
|
L
 -22.2%
H
21.3
30.0
|
L
 -28.0%
H
21.3
32
|
L
 -28.0%
H
21.3
32
|
L
 -28.0%
H
21.3
32
|
L
 -28.0%
H
21.3
32
|
L
 -28.0%
H
21.3
32
|
| BioStem Technologies Inc |
|
68.2
|
3.8
|
L
 -4.5%
H
3.8
4.1
|
L
 -5.2%
H
3.8
5.4
|
L
 7.3%
H
3.4
5.4
|
L
 -7.1%
H
2.3
5.4
|
L
 -7.1%
H
2.3
5.4
|
L
 -7.1%
H
2.3
5.4
|
L
 -7.1%
H
2.3
5.4
|
L
 -7.1%
H
2.3
5.4
|
| Vogenx Inc |
|
399.0
|
26.9
|
L
 1.1%
H
26
27.9
|
L
 -16.6%
H
24.1
38.4
|
L
 -9.0%
H
24.1
38.4
|
L
 106.6%
H
13
38.4
|
L
 106.6%
H
13
38.4
|
L
 106.6%
H
13
38.4
|
L
 106.6%
H
13
38.4
|
L
 106.6%
H
13
38.4
|